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ABSTRACT 26 
 27 
Brucellosis is an important zoonotic disease affecting about 500,000 people annually. 28 
The development of safer and more efficacious Brucella Live attenuated vaccines 29 
addresses safety concerns that include the identification of reproducible and reliable 30 
surrogates of protection and mechanisms to bolster longevity. Brucella encodes a toll 31 
interleukin receptor domain containing protein (TcpB/Btp-1). These proteins subvert 32 
host innate immunity by abrogating NF-κB mediated cytokine production, by binding to 33 
and/or causing the degradation of signaling molecules TIRAP (MAL) and MyD88. TcpB 34 
has also been shown to directly reduce the CTL killing activity of infected host cells.  35 
In the current study, we investigated the effect of deleting tcpB from Brucella on invitro 36 
and invivo immune responses. We also evaluated an in vitro murine Brucella growth 37 
inhibition co-culture assay to determine the capacity of immune splenocytes from mice 38 
exposed to the tcpB mutant or wild type to control the growth of Brucella melitensis in 39 
murine bone marrow derived macrophages. A tcpB knockout constructed by gene 40 
replacement in the Brucella abortus S19 genetic background was used to vaccinate 41 
C57BL/6 mice assessed for development of CD4+ memory T cells. Mice vaccinated with 42 
the mutant displayed an elevated Th1 response, compared to the parental S19 and non- 43 
vaccinated controls, as manifested by multiple factors. These include; elevated IFN-γ 44 
early post vaccination, and a significant elevation of memory CD4+CD44+CD62L+ 45 
within CD4+T cell population in splenocytes derived from mice vaccinated with the 46 
mutant. S19 and S19∆tcpB strains induced a significant increase in the IgG2a levels post 47 
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vaccination.  Consistent with a shift to a Th1 response, S19∆tcpB induced a higher 48 
response later in vaccination.  Splenocytes obtained from mice vaccinated with the 49 
S19∆tcpB mutant exhibited significantly higher levels of killing activity compared to 50 
cells derived from S19 vaccinated mice and PBS controls. Consistent with enhanced 51 
immune protection, fewer bacteria were recovered from the spleens of mice vaccinated 52 
with the S19∆tcpB mutant, which had reduced inflammatory lesions consistent with 53 
reduced bacterial burden. These results provide strong evidence that tcpB deletion 54 
improves immunogenicity, longevity and protective efficacy of S19 and that ex vivo co- 55 
cultivation may be employed to predict potential vaccine efficacy. 56 
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CHAPTER I 288 
INTRODUCTION AND LITERATURE REVIEW: 289 
TOLL INTERLEUKIN-1 RECEPTOR (TIR) DOMAIN CONTAINING 290 
PROTEINS  (ΔTCPB) DELETION MUTATION: A NOVEL BRUCELLA 291 
VACCINE IMPROVEMENT STRATEGY 292 
 293 
1.1 Background 294 
1.1.1 Brucellosis 295 
Brucellosis is an important zoonotic disease caused by facultative intracellular bacteria 296 
of the genus, Brucella. Brucella spp belong to family Brucellaceae in the α2 subdivision 297 
of the phylum Proteobacteria.  These are small, non-motile, non-spore forming, aerobic 298 
or microaerophilic, Gram-negative coccobacilli [1]. Ten species of Brucella have been 299 
identified based on their preferred hosts; these are B. abortus (cattle), B. melitensis 300 
(sheep and goats), B. ovis (sheep), B. canis (dogs), B. suis (pigs), B. neotomae (desert 301 
woodrat), B. pinnipedialis (seal), B. ceti (dolphin, porpoise, whale), B. microti (common 302 
vole) and B. inopinata (unknown). All members of the genus are closely related 303 
genetically and immunologically [2]. Of these, B. abortus, B. melitensis, B. suis, and B. 304 
canis are pathogenic to humans [3]. Brucella strains may exist as either smooth or rough 305 
variants depending on the expression of O-polysaccharides (OPS), which is a major 306 
component of the bacterial outer membrane lipopolysaccharide (LPS) [4]. The smooth 307 
LPS (S-LPS) expresses the OPS, which is responsible for host antibody responses. The 308 
 2 
absence of OPS on R-LPS determines a rough phenotype, which is associated with lost 309 
of invasion, clearance from host tissues and virulence [5,6]. 310 
Brucella infections are characterized by preference for cells of the reticulo-endothelial 311 
system and reproductive organs. The organism colonizes and persists in tissue 312 
macrophages, dendritic cells and is carried to many parts of the body. Infection of the 313 
placental trophoblasts causes necrosis of the fetal cotyledons, suppurative placentitis and 314 
abortion in the female. Abortion occurs in the fifth month of gestation and the fetus may 315 
be autolysed. Infection in bulls is manifested by seminal vescicultis and orchitis that may 316 
cause sterility [7,8]. In addition to brucellosis severely impairing the reproductive 317 
potential of a herd by impacting negatively on productivity; the disease has a severe 318 
public health importance, causing an acute and chronic disease in humans [9]. Control of 319 
the disease in humans is through animal vaccination or culling, as no vaccine is licensed 320 
for use in humans. 321 
 322 
1.1.2 Impacts of brucellosis on human health 323 
Although human brucellosis has almost been eradicated in many developed countries, it 324 
remains a major neglected zoonosis of low-income nations [10].  The disease negatively 325 
impacts agriculture, and is a major public health hazard affecting about additional 326 
500,000 people annually [3,11]. The disease manifests in humans in an acute or chronic 327 
debilitating course; the most common signs include undulating fever, headaches, chills, 328 
depression, weakness, arthralgia, myalgia and weight loss [12]. The disease may also 329 
present as a reproductive form manifesting as orchitis/epididymitis in men and 330 
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spontaneous abortion in pregnant women [13,14]. The disease can take a chronic course 331 
accompanied by complications like endocarditis, arthritis and osteomyelitis [15,16]. 332 
Treatment of brucellosis in humans involves a prolonged antibiotic course, the optimal 333 
treatment regimen being a doxycycline-aminoglycoside-rifampicin combination, with 334 
the aminoglycoside administered for the first seven to 14 days and doxycycline- 335 
rifampicin combination continued for six to eight weeks [17]. Transmission of B. 336 
abortus, B. melitensis, B. suis and B. canis between animals occurs by contact with 337 
discharges from the placenta, fetus and the reproductive tract from infected animals. 338 
Transmission from animals to humans may occur as an occupational hazard, involving 339 
people that work with farm animals or come into contact with environments 340 
contaminated by animal products. These may include farmers, animal attendants, 341 
stockmen, shepherds, sheep shearers, goat herders, pig keepers, veterinarians and 342 
inseminators. Infection may occur by inhalation, conjunctival contamination, accidental 343 
ingestion, skin contamination through abrasions, or accidental self-inoculation with live 344 
vaccines in laboratory workers [18]. Clinical signs in humans are often incorrectly 345 
interpreted by medical personnel, and as a result, human brucellosis is severely 346 
underreported or ignored [19]. 347 
 348 
1.1.3 Impacts of brucellosis on agriculture 349 
Livestock rearing is the principal economic activity supporting livelihoods of more than 350 
50% of the population in sub Saharan Africa [20]. Many diseases that affect both 351 
livestock and humans like brucellosis are poorly controlled due to lack of financial 352 
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resources [21]. Brucellosis has been recognized as one of the most important and 353 
widespread zoonosis in sub Saharan Africa [21]. The disease not only affects human 354 
health, but also their socio economic livelihoods through the health of their livestock 355 
[10,22]. The negative impact on the livestock sector is primarily due to abortion or 356 
stillbirths, weakened or sickened calves, decreased milk production and infertility [10]. 357 
The latter is a result of prolonged inter-calving intervals due to stillbirths and abortions, 358 
and increased periods between lactations and the costs involved in control.  Economic 359 
losses in small ruminants manifest as suboptimal breeding resulting from infertility in 360 
rams and reduced milk production [21]. In developed countries, mandatory testing and 361 
depopulation is the method of choice in disease control and management of infected 362 
herds.  Infected animals are eliminated, and owners are paid a federal indemnity. In 363 
addition to the loss of valuable income, this culling slows the genetic progress to 364 
improving the quality of the herd by reducing the genetic pool and reduces export trade 365 
of any affected state [23].  366 
 367 
1.1.4 Significance of the work performed 368 
The negative impacts of endemic brucellosis cut across agriculture, public health and 369 
social development sectors. It is therefore important to control the disease in order to 370 
improve the socio-economic livelihood of affected communities. Management of the 371 
disease relies heavily on vaccination in the animal population, and the best course of 372 
action is removal of the infected animals from the herd. However, currently available 373 
vaccines are unsafe for use in pregnant animals, and may induce abortion. Their use can 374 
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therefore exacerbate the threat to human health in the absence of a licensed vaccine for 375 
use in humans and a prolonged and often unsuccessful therapeutic management [24].  376 
Live attenuated vaccines (LAV) against brucellosis present the best method of control 377 
due to the elevated, long lived immunity they engender [25]. Generation of Brucella live 378 
attenuated vaccines can be naturally obtained by spontaneous or targeted deletions of 379 
virulence genes from wild type strains [26]. Several vaccines have been generated and 380 
have demonstrated successful use [25-27]. However, these vaccines have several side 381 
effects including residual virulence, abortion in pregnant animals, and ability to cause 382 
disease in humans [25]. Use of B abortus S19 (also referred to as S19) vaccine in field 383 
conditions has been associated with abortions when administered to pregnant animals at 384 
rates between 1 and 2.5% [28]. In experimental conditions, attenuated B. abortus S19 is 385 
transmitted to the fetus and often causes higher abortion rates [29,30]. Several attempts 386 
have been made to develop safer Brucella LAV, by identifying and deleting virulence 387 
genes and providing improved delivery systems with varying results [31]. In contrast to 388 
those studies, we have hypothesized that the presence of immuno-subversive factors may 389 
be explored in the quest for safe and efficacious Brucella live attenuated vaccines.  390 
Recent studies have revealed that Brucella genomes bear genes encoding factors that 391 
subvert toll like receptor (TLR) and host innate immune responses.  These are proteins 392 
that mimic the toll interleukin 1 receptor, including Brucella toll interleukin-1 receptor 393 
domain containing proteins (TcpB/Btp1 and Btp2) [32,33]. The presence and activity of 394 
these factors may compromise the efficacy and safety of LAV. Deletion of genes 395 
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encoding these factors from live attenuated vaccines offers a novel strategy for 396 
improving their safety and/or efficacy. 397 
 398 
1.1.5 Innovation associated with the project 399 
TcpB/Btp1 and Btp2 proteins expressed by Brucella have significant subversive effects 400 
on the host immune resistance to Brucella infection [33]. TcpB binds to components of 401 
the TLR signaling pathway, Myeloid differentiation factor 88 (MyD88) and Toll 402 
interleikin-1 receptor adaptor protein (TIRAP), causing TIRAP degradation and 403 
subverting innate immunity and enhancing pathogen establishment and survival [34,35].  404 
Subsequent studies have shown that mutants defective in TcpB expression up-regulate 405 
host innate immune mechanisms during Brucella infection by stimulating enhanced pro 406 
inflammatory cytokine secretion [32]. In addition, TcpB also reportedly subverts T cell 407 
activity and contributes to the establishment of chronic brucellosis [36]. The net effect of 408 
expression of TIR containing proteins like TcpB during Brucella infection is host 409 
immune subversion and enhancement of pathogen survival. The flip side of this coin is 410 
that the absence of TcpB expression is expected to result in an enhanced innate immune 411 
response potentially improving vaccine efficacy.  The goal of this project was to design 412 
safer and more efficacious Brucella live attenuated vaccines by introducing a tcpB 413 
mutation to Brucella LAV (S19) and to use this novel vaccine to identify correlates of 414 
immune protection against brucellosis. The specific aims of the research included 415 
construction of a tcpB deletion mutant of Brucella abortus S19 and evaluation of the 416 
resulting innate and adaptive immunity and protective efficacy in a murine model of 417 
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brucellosis. The central hypothesis of the objective was that tcpB deletion mutant would 418 
confer improved immunogenicity and protective efficacy to the currently available 419 
vaccine strain B. abortus S19. 420 
 421 
1.2 Problems unique to intracellular pathogens 422 
Intracellular bacteria reside within macrophages, dendritic cells or other cells of the 423 
reticulo-endothelial system, a niche that provides unique physicochemical conditions 424 
that impact both the survival of the pathogen and the host. Intracellular bacteria are 425 
therefore faced with a task of developing mechanisms that render them inaccessible to 426 
the antimicrobial effector mechanisms of the host while providing nutrients necessary 427 
for survival and proliferation. Intracellular pathogens have therefore evolved 428 
mechanisms enabling them reside within the hostile environment of macrophages or 429 
other cells of the reticulo-endothelial system [37]. Upon infection by bacteria, 430 
macrophages deploy a wide range of killing mechanisms, these may include, secretion of 431 
proinflammatory cytokines, activation of intracellular pathogen killing and activation of 432 
Th1 cell responses [38]. Bacteria have therefore developed mechanisms of inhibiting or 433 
modifying these mechanisms in their favor.  434 
 435 
1.3 Microbial mechanisms of host immune evasion 436 
1.3.1 Lysosomal degradation 437 
Following phagocytosis, engulfed bacteria are located in phagosomes, which 438 
subsequently fuse with lysosomes, acidify and mature into phagolysosomes. 439 
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Phagolysomes contain proteases, antimicrobial peptides, and lysozyme that mediate the 440 
killing of the engulfed bacteria. Intracellular bacteria have developed various ways of 441 
avoiding phagosomal maturation and fusion with the lysosome [39]. These mechanisms 442 
may range from enclosure in a vacuole resistant to lysosomal fusion, or expression of 443 
factors that neutralize the lysosomal effectors [40]. Brucella is enclosed in a Brucella 444 
containing vacuole (BCV) that is resistant to lysosomal degradation [41].  445 
 446 
1.3.2 Nutrient access 447 
Since location in lysosome resistant compartments presents a problem of access to 448 
nutrients, bacteria may need the lysosomal processes to acquire nutrients [42]. Cells use 449 
the autophagic process by enclosing dead organelles in autophagosomes and fuse them 450 
with lysosomes for degradation. Autophagy may play a dual role in host defense by 451 
encapsulating and degrading microbes, but it may also facilitate delivery of nutrients to 452 
enclosed pathogens [43]. Brucella has been documented to induce the unfolded protein 453 
response, which may activate autophagic processes that enhance its survival. The 454 
unfolded protein response mediated autophagy been proposed to be a mechanism of 455 
nutrient acquisition by Brucella and is responsible for enhancing its survival [44] 456 
 457 
1.3.3 The oxidative burst 458 
The oxidative burst is a release of reactive oxygen species [superoxide radical (O-2) and 459 
hydrogen peroxide (H2O2)] by macrophages following contact with microorganisms. 460 
Macrophages use NADPH oxidase to reduce O2 to O-2 and then to H2O2 [45]. 461 
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Macrophages also use the interaction of myeloperoxidase with H2O2 and Cl− to generate 462 
hypochlorite, which is toxic to most bacteria. Brucellae are protected from the 463 
respiratory burst of host macrophages by expression of superoxide dismutase (SOD) 464 
encoded by sodC. These enzymes catalyze the dismutation of superoxide (O2−) to 465 
hydrogen peroxide (H2O2), which can then be further detoxified through the action of 466 
catalases and peroxidases[46]. 467 
 468 
1.3.4 Macrophage response to cytokine activation 469 
Macrophages respond to bacterial infection by activating signaling cascades leading to 470 
expression of pro-inflammatory cytokines such as IL-12, TNF-α, and IFN-γ [47]. These 471 
cytokines either activate intramacrophage killing of the bacteria or enhance the adaptive 472 
immune response by up regulating T cell activity. They may also induce production of 473 
anti-inflammatory cytokines such as IL-10, TGF-β, and IL-4 to down-regulate host 474 
defense mechanisms [48]. Brucella may also trigger down regulation of signaling 475 
pathways that trigger programmed cell death 476 
When macrophages fail to control the pathogen, they may use programmed cell death as 477 
a way of pathogen elimination [43]. This may occur by either apoptosis, pyroptosis or 478 
necrosis [49]. Apoptotic cells are then engulfed by neighboring phagocytes, causing 479 
pathogen degradation and presentation of peptides to CD8+T cells I the context of MHC 480 
class 1 [50].  Necrosis and pyroptosis can trigger rapid inflammation, due to secretion of 481 
pro-inflammatory cytokines via extracellular release of cytoplasmic contents [51]. 482 
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Intracellular Brucella can also use programmed cell death or cytotoxicity as a strategy 483 
for egress and possible cell-to-cell spread [52,53].  484 
 485 
1.4 Host response to Brucella infection 486 
1.4.1 Innate immunity 487 
1.4.1.1 NF-κB mediated TLR pathway 488 
Early in infection, the TLRs expressed by the host cell recognize pathogen-associated 489 
molecular patterns (PAMPs) from bacterial cells [54]. This triggers protective innate 490 
immune responses, including expression of proinflammatory cytokines and co 491 
stimulatory molecules [55]. TLR signaling therefore significantly affects the host innate 492 
and adaptive immune responses [56]. However, Brucella spp lack structures that 493 
commonly activate classic TLR signaling and a strong innate immune response; 494 
including, possession of non-classic LPS, capsules, fimbriae and pili, and a flagellum 495 
that escapes recognition by TLR5 [57]. Under classic conditions, potent TLR 496 
engagement stimulates interaction with specific, TIR adaptors, MyD88, MyD88-adapter- 497 
like (MAL)/TIRAP, TIR domain containing adaptor inducing IFN-β (TRIF) or TRIF- 498 
related adapter molecule (TRAM). However, Brucella infection does not induce strong 499 
innate immune responses due in part to the poor agonist activity of Brucella PAMPs and 500 
to TcpB-dependent abrogation of TLR signaling [58]. TcpB binds to TIRAP and myD88, 501 
causing degradation of TIRAP and abrogation of the MyD88 mediated signaling 502 
pathway. The net action of TcpB is abrogation of NF-κB translocation and inhibition of 503 
expression of proinflammatory cytokines.  The cytokines produced by APCs direct the 504 
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differentiation of CD4+ T cells to either Th1 or Th2 cells. Activation of TLR signaling 505 
pathways therefore significantly affects the type of CD4+ T cell differentiation [59]. 506 
Brucella infection restricts the host’s innate immune response by expressing LPS with 507 
reduced agonist activity to enhance efficient invasion and establishment in addition to 508 
limiting the priming of an effective adaptive immune response. It has, however, been 509 
found that toll like receptors play a significant role in of Brucella infections. 510 
Experimental evidence has shown that TLR 2, 4 and 9 play important roles in aiding 511 
clearance, susceptibility, and dissemination of Brucella in the host [60].  Experimental 512 
evidence has shown that TLR 2,4, 9 and MyD88 KO mice have enhanced susceptibility 513 
to Brucella, and that this enhanced susceptibility has been attributed to reduced 514 
expression of pro-inflammatory cytokines, reduced uptake and dissemination [60-62]. 515 
Due to the MyD88 subversive effect of tcpB, it is expected that tcpB bearing wild type 516 
B. abortus will significantly impact the infectivity and dissemination of Brucella. 517 
MyD88 has, however, been shown to be more important than TLR2, 4 and 9 in clearance 518 
of Brucella infections [63-65]. The subversive effect of tcpB to MyD88 is therefore 519 
expected to have a negative impact on the host response to Brucella. 520 
 521 
1.4.1.2  Mitogen activated kinase (MAPK) mediated TLR pathway 522 
TLR activation by Brucella and subsequent production proinflammatory cytokines also 523 
involves activation of the mitogen-activating protein kinase-signaling pathway (MAPK) 524 
[66]. The MAPK signaling cascade has been described in bacterial pathogenesis as 525 
demonstrated by the induction or inhibition of ERK1/2 and p38 MAPKs during 526 
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Mycobacterium spp [67]. The differences in inflammation associated with smooth and 527 
rough Brucella have been explained by differential activation of MAPK. Smooth 528 
Brucella have been shown to mildly activate the MAPK while activation is greatly 529 
enhanced by the rough bacteria, this has been associated with the presence and absence 530 
of the LPS O chain that leads to up regulation of TLR signaling[68]. 531 
 532 
1.4.2 Host adaptive immune mechanisms in brucellosis 533 
Following phagocytosis by antigen presenting cells (APCs), Brucellae are enclosed in a 534 
Brucella containing vacuole (BCV) which releases antigens that become associated with 535 
MHC class II which traffic to the cell membrane where they are presented to CD4+T 536 
cells. The normal outcome is activation of T cells that includes both enhanced cytotoxic 537 
activity and MyD88 dependent secretion of a variety of chemokines and cytokines 538 
including; IL-12, IL-1, IL-6, TNF-α and IFN-γ to initiate an innate immune response 539 
[65]. IL-12 initiates clonal expansion of Th1 cells, and stimulates production of IFN-γ 540 
and TNF-α from T cells and NK cells while reducing IL-4 expression. IL-12 also 541 
enhances the cytotoxic activity of NK cells and CD8+ T lymphocytes demonstrated 542 
experimentally by increasing innate and adaptive immunity in Brucella-susceptible mice 543 
treated with IL-12 [69,70]. IFN-γ is a critical cytokine for host control of Brucella 544 
infection [71]. IFN-γ activates the cytotoxic action of CD8+ T cells on Brucella infected 545 
cells, by activating macrophages and by inducing class II major histocompatibility 546 
complex (MHC) molecule expression on antigen presenting cells [72]. TNF-α, another a 547 
pro-inflammatory cytokine produced during Brucella infection drives the secretion of 548 
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IL-12 and IFN-γ, directing an acquired secondary response of the Th1 phenotype by 549 
CD4+ and CD8+ lymphocytes [73]. Th1 cells play an important role in the control of 550 
Brucella infection. Although immunity to Brucella spp. requires both CD4+ T cells and 551 
CD8+ CTLs [74], there are conflicting reports as to which plays a more important role. 552 
Several studies describe the importance of CD8+ cells based on the absence of β2 553 
macroglobulin significantly exacerbating infection [75-77]. β2 macroglobulin is an 554 
essential component of MHC class I, and is present on all nucleated cells. Lack of β2 555 
macroglobulin therefore compromises antigen presentation to CD8+ T cells via MHC 556 
class I [78].   Furthermore, in vivo depletion has also revealed that CD8+ T cells are the 557 
primary responders to DNA vaccines encoding outer membrane proteins and reduction 558 
in number results in higher bacterial loads in B. abortus infected BALB/c mice [79,80]. 559 
Brucella-specific CD8+T cells play a dual role in control of Brucella infection; they 560 
initiate lysis of Brucella-infected macrophages and also secrete low levels of IFN-γ that 561 
enhances macrophage killing of intracellular bacteria [74]. It has, however, been shown 562 
that IFN-γ–producing CD8+ T cells alone fail to protect mice during primary infection 563 
[81]. CD4+ T cells have been shown to display a variety of helper functions necessary 564 
for an efficient adaptive immunity. CD4+ T cells produce IFN-γ that promotes intra- 565 
macrophage killing of Brucella-infected cells.  CD4+ CTLs are also capable of cytolytic 566 
action against Brucella-infected APC [82]. This suggests that both CD4+ and CD8+ T 567 
cells may a play a synergistic role in the anti-Brucella activity [74]. Deletion of tcpB 568 
from live attenuated vaccines may result in increased expression of CD4+ and CD8+ T 569 
 14 
cells by virtue of the increased expression of pro inflammatory cytokines that are 570 
induced early in infection.  571 
 572 
1.5  Brucella-specific resistance to host immune mechanisms 573 
1.5.1 Resistance to innate immunity 574 
Brucella infections are characterised by subversion of innate immune rsponses that leads 575 
to persistence in tissues and failure of the host to clear the infection. This is suspected to 576 
derive from the cell surface lipopolysaccharide composed of a relatively non-toxic lipid 577 
A structure composed of unusually long chain fatty acids and an O-antigen 578 
homopolymer  of N-formyl perosamine.  The absence of O-antigen results in “rough” 579 
variants which induce elevated inflammatory responses accountable for the highly 580 
attenuated virulence of these organisms [83,84].  In the absence of documented changes 581 
in the lipid A in rough organisms,  this difference is attributable to the loss of O-antigen 582 
sidechains alone. Following phagocytosis, the organism relies upon the type IV secretion 583 
system (T4SS) to survive by secreting effector proteins to alter the intracellular 584 
environment and intracellular trafficking of Brucella containing vacuoles to provide a 585 
replicative niche [85]. One of these effectors, VceC, activates a proinflammatory 586 
response via the unfolded protein response (UPR) via the endoplasmic reticulum (ER). 587 
These two factors appear to control contradictory results, but it is important to recognize 588 
that these activities operate at different stages of infection. The contribution of TIR- 589 
containing proteins like TcpB/Btp-1 and Btp-2 have only recently been revealed [32,33]. 590 
Encoded within the bacterial genome, TcpB and Btp-2 encode proteins which are 591 
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molecular mimics of host proteins that interfere with host cell signaling pathways by 592 
interacting with pathway components and altering host cell functions. For example, 593 
TcpB prevents TIRAP-mediated recruitment of MyD88 to the plasma membrane (PM) 594 
resulting in a failure of TLR4/2 signaling [86]. The Brucella TIR proteins also have 595 
phosphatidyl inositol (PtdIns) binding sites similar to host cell factors that contribute to 596 
PM localization to enhance TIR:TIR interactions. Whether TcpB can reduce intracellular 597 
PIP2 levels in an effort to regulate cell function has not been addressed. Strains lacking 598 
TcpB would be expected to exhibit an enhanced proinflammatory response due to a 599 
reduction in the inhibitory affect of TIRAP binding with MyD88 which enhances 600 
TLR4/2 signaling and the UPR and an associated improvement in the adaptive immune 601 
response.  602 
 603 
1.5.2 Brucella lipopolysaccharide (LPS) 604 
Brucella possesses a non-classical LPS with weak agonistic activity to TLR as compared 605 
with the potent endotoxin produced by Escherichia coli [87]. This difference is 606 
attributable to the presence of long chain fatty acids conjugated to the lipid A portion of 607 
the Brucella LPS.  Brucella lipid A possesses a di-aminoglucose backbone with long 608 
acyl groups (C28), which are linked to the core by amide bonds. The reduced potency of 609 
Brucella LPS is thought to represent an evolutionary adaptation that avoids activation of 610 
the early host innate immune response and leads to early establishment of the infection 611 
and acquisition of a BCV [88,89].  612 
 613 
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 614 
1.5.3 The two-component system (BvrR/BvrS)  615 
This is an adaptive mechanism used by Brucella to regulate the expression of specific 616 
genes in response to changes in environmental conditions. The two components include 617 
an environmental sensor (BvrS), a histidine kinase found on the cytoplasmic membrane 618 
that transmits a signal to the second component, a cytoplasmatic response regulator 619 
(BvrR) that mediates changes in gene expression [90]. Environmental stimuli are 620 
detected by BvrS that undergoes autophosphorylation on a histidine residue. The 621 
phosphorylation generates a series of reactions that activate transcription factors 622 
inducing expression of specific host genes [91]. Brucella uses this system for the 623 
expression of genes involved in the maintenance of cell envelope integrity including 624 
multiple members of the Omp3 family of proteins, Omp25, Omp22 or Omp3b [92]. This 625 
system also regulates genes that modify the fatty acid composition of the lipid A moiety 626 
of the LPS. This system also controls the expression of the virB type 4-secretion system 627 
(T4SS) via BvrR binding at the virB promoter and activating the transcription of VjbR a 628 
master regulator of expression of Brucella virulence factors [90].  629 
 630 
1.5.4 The Brucella type 4 secretion system (T4SS) 631 
The Brucella type IV secretion system (T4SS) is a bacterial organelle comprised of 12 632 
proteins exposed on the surface of the bacterial cell envelope. Its main function is to 633 
translocate effector proteins from Brucella into infected host cells. The virB operon 634 
encoding the Brucella T4SS consists of 12 open reading frames virB1 to virB12 (loci 635 
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BMEI10025-BMEI10035) controlled by a single promoter just upstream of 636 
virB1[93,94]. The T4SS is expressed in response to acidification and/or partial 637 
lysosomal fusion with the BCV. The acidified BCV acquires the late endosome markers 638 
LAMP-1, CD63 and Rab7 [95], then progressively looses these markers and associates 639 
with the ER exit sites as determined by accumulation of the ER markers calreticulin, 640 
Rab2 and GAPDH.  Acquisition of these markers is associated with conversion of the 641 
BCV into a replicative BCV (rBCV). Expression of the T4SS is required for maturation 642 
of the BCV following sustained interaction and fusion with the endoplasmic reticulum 643 
[96]. VjbR, a LuxR family transcriptional regulator, promotes expression from the virB 644 
operon by directly binding to a region of the virB promoter containing an 18 bp 645 
palindromic motif [93]. Also among the genes activated by VjbR are two novel T4SS 646 
effectors, VceA and VceC [97]. Five additional T4SS effectors that may play a role in 647 
persistence of Brucella have been described; these are BAB1_0678 (BspA), BAB1_0712 648 
(BspB), BAB1_0847 (BspC), BAB1_1671 (BspE) and BAB1_1948 (BspF) [85].  649 
 650 
1.5.5 Cyclic beta-1, 2 glucans (CβG) 651 
CβG is a virulence factor expressed by Brucella that interrupts host cellular functions 652 
like causing perturbation of intracellular trafficking to benefit the pathogen [98]. CβG 653 
interacts with cholesterol and interferes with lipid rafts and intracellular trafficking to the 654 
pathogen’s advantage. Brucella CβG deficient mutant strains display a defect in 655 
intracellular trafficking in epithelial cells. This deficiency can be complemented by 656 
addition of purified CβG [98]. 657 
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 658 
1.5.6  Brucella TIR domain containing proteins 659 
Brucella encodes and expresses TIR domain containing proteins, which are implicated in 660 
enhancing virulence by subversion of host immune responses [33]. These proteins 661 
suppress TLR signaling by subverting NF-κB activity, reducing the host inflammatory 662 
response and enhancing infection of the “stealth” pathogen [99]. Three dimensional 663 
crystallography studies have shown that TIR containing proteins are composed of 664 
uniform structures of five stranded parallel β sheets and five α helices connected by 665 
surface exposed loops [100]. A BB loop connects the B sheet to the B helix and has been 666 
shown to be important for signal transduction and microtubule-binding site [101,102]. 667 
Their function stems from the shared sequence homology they have with mammalian 668 
TIR domains [103]. The greatest similarity between Brucella and mammalian TIR 669 
proteins is found in domains designated box 1, box 2, and box 3 [58]. The features in 670 
these areas are highly conserved in both the mammalian and the bacterial TIR domains. 671 
The consensus protein sequences for box 1 is (YDAFISYS), box 2 672 
(LKLCLXXRDXXPGXSI), while box 3 has a conserved W surrounded by basic 673 
residues. It has been proposed that boxes 1 and 2 are involved in the binding to TIRAP 674 
and MyD88, whereas box 3 is primarily involved in localizing proteins to microtubules 675 
[34,86,104].  TcpB binds to both MyD88 and TIRAP, but the binding to MyD88 occurs 676 
via death domains (DD) and is stronger than TIRAP binding [34]. MyD88 forms a 677 
central adaptor in the TLR family signaling pathways by linking TLR family members to 678 
IL-1R-associated kinase (IRAK) family kinases [105]. The C-terminal TIR (Toll IL-1R) 679 
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domain interacts with other TIR domain-containing proteins; the N-terminal death 680 
domain (DD) associates with the IRAK family members [106]. Activation of IRAK 681 
kinases leads to activation of nuclear factor-kappa B (NF-κB), mitogen-activated protein 682 
kinases (MAPK), and activator protein and subsequently expression of pro inflammatory 683 
cytokines. Binding of MyD88 DDs to IRAK DD forms a structure, termed the 684 
Myddosome, comprising of a ring of six MyD88 DDs that serve as a seed for assembly 685 
of a ring of four IRAK4 DDs and ultimately four IRAK2 DDs in a helix. The 686 
Myddosome forms a scaffold for the assembly of downstream signaling molecules 687 
[105]. Binding of Brucella TcpB to MyD88 prevents assembly of the activated 688 
Myddosome complex, thus preventing downstream signaling [107]. The result is 689 
abrogation of translocation of NF-kB into the nucleus and reduced transcription of genes 690 
expressing proinflammatory cytokines [108] . The binding of TcpB to the DD of MyD88 691 
or binding to TIRAP and subsequent TIRAP degradation causes subversion of host cell 692 
signaling that aid in the establishment of infection [86]. Brucella ∆tcpB mutants may be 693 
expected to stimulate an enhanced innate response and provide improved immune 694 
protection.  695 
 696 
1.5.7    TcpB: Phosphoinositide (PIPs) binding and immune subversion 697 
Phosphoinositides, the phosphorylated derivatives of phosphatidylinositol (PI), regulate 698 
many critical cell processes involving membrane signaling, trafficking, and 699 
reorganization [109].   Sequence analysis confirms that TIRAP shares phosphoinositide- 700 
binding domains similar to those identified in the Brucella TcpB protein [86]. This 701 
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binding enhances TcpB co-localization with the plasma membrane and components of 702 
the cytoskeleton [110].  Phosphoinositides participate centrally in several cell signal 703 
transduction activities in addition to structural and developmental functions [111,112]. 704 
By virtue of PIP binding, TcpB is expected to participate in structural and signaling 705 
properties of cells to facilitate Brucella infection and dissemination [86]. 706 
Phosphoinositides play an important role in the organization and rearrangements of the 707 
actin cytoskeleton and in phagosomal maturation during classical phagocytosis. Bacteria 708 
utilize phosphoinositides to recruit effectors required to facilitate invasion and enhance 709 
maturation of intracellular compartments that promote bacterial survival [113]. These 710 
observations prompted studies to confirm that TcpB targets the TLR-TIRAP-mediated 711 
signaling pathway to subvert NF-κB translocation by binding to and promoting 712 
ubiquitination of TIRAP [58,86]  713 
 714 
1.5.8 TcpB effect on unfolded protein response (UPR) and innate immunity 715 
B. melitensis infection triggers UPR in order to facilitate its survival after infection by 716 
activating all three branches of UPR signaling in macrophages; IRE1, PERK and ATF6 717 
[44]. Brucella mediated activation of UPR has been shown to be associated with TcpB 718 
[44]. TcpB has a strong MyD88 binding affinity that is predicted to disrupt UPR 719 
mediated expression of proinflammatory cytokines [44]. Brucella therefore uses TcpB to 720 
inhibit XBP-1 splicing, a critical branch of UPR, to subvert cytokine production [114]. 721 
Thus, expression of TcpB may suppress cytokine gene expression via MyD88 binding 722 
and subsequent TIRAP degradation, leaving two of the three arms of the UPR active.  723 
 21 
 724 
1.5.9 Brucella ∆tcpB mutants in the mouse model 725 
Due to its mechanism of abrogation of NF-κB translocation, Brucella TIR domain 726 
containing proteins reduce pro inflammatory cytokine expression. In studies performed 727 
with B. abortus TIR mutants, deletion of BtpA and BtpB resulted in significant increase 728 
in secretion of TNF-α in BMDCs [32,115]. Deletion of BtpB was also shown to 729 
upregulate the proinflammatory cytokine IL-12 in BMDCs [32]. Analysis of cytokine 730 
expression in infected IRF-1–/– mice infected has also shown upregulation of TNF-α in 731 
animals infected with TcpB-deficient Brucella compared with the wild type [86]. Studies 732 
comparing survival of Brucella ∆tcpB mutants and wild type bacteria in a mouse model 733 
have shown that ∆tcpB mutants exhibit an early attenuated phenotype in mice that is 734 
resolved at later time points [86]. Mice infected with the ∆btpB mutant also survive 735 
longer than those infected with the wild type B. abortus [32]. Histological examination 736 
of spleens obtained from wild type BALB/c mice revealed a significantly higher number 737 
of granulomas in mice infected with ∆btpB and ∆btpA∆btpB [32]. Granuloma formation 738 
may reflect the host's ability to develop a protective immune response. Increased 739 
granuloma formation in infection by ∆btpB and ∆btpA∆btpB mutants therefore suggests 740 
that tcpB deletion increases the host’s ability to develop a protective immune response in 741 
LAV. Mice infected or vaccinated with tcpB LAV mutants are therefore expected to 742 
show elevated immune response, making the case for tcpB deletion in LAV as an 743 
attractive vaccine development strategy. 744 
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1.6  Brucella vaccines 745 
Studies have established that the ability of a Brucella vaccine strain to multiply in the 746 
host before clearance was a condition necessary to trigger protective immunity, making 747 
the case for live attenuated vaccines [116].  A degree of persistence in host tissues 748 
without causing pathology may be a favorable factor in designing LAV [25]. The best 749 
available vaccine against Brucella (B. abortus S19 and B. melitensis Rev 1) are live, 750 
attenuated strains that persist in tissues for some time [117]. Brucella virulence genes are 751 
related to induction of virulence, persistence may, therefore, be partly associated with 752 
the side effects observed [118]. Brucella LAV may cause abortion in pregnant animals 753 
and interference with serological diagnosis, and virulence for humans [7]. Efforts to 754 
improve LAV have focused on creating deletion mutants with reduced persistence and 755 
virulence [26,116,119,120]. However, this strategy has also resulted in reduced efficacy 756 
[25]. To address the problem created by reduced efficacy, improved delivery methods 757 
and additional immune enhancing mutations may be introduced [25]. Multiple 758 
experimental live attenuated vaccines with varying efficacy have been created for use 759 
against brucellosis in animals. These LAV against brucellosis have been designed by 760 
identification and deletion of genes encoding virulence factors [31,121,122]. Deletion of 761 
these genes confers upon the vaccines increased safety.  Attempts have also been made 762 
to improve delivery platforms of LAV in order to improve their efficacy [123].  763 
Attempts have also been made at designing subunit vaccines by expressing 764 
immunogenic peptides from Brucella and optimizing the expression systems [124]. An 765 
example of a promising LAV has been made by deletion of the, vjbR gene that encodes 766 
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the quorum sensing regulator. The resulting mutant made from the strains B. melitensis 767 
16M is rapidly cleared from mice manifested as a drastic reduction in splenic CFU 768 
burden by 28 days post-infection [31]. This deletion confers protection against B. 769 
melitensis similar to Rev-1 vaccine [26].  The efficacy of this strain has been further 770 
enhanced by microencapsulation of a related mutant B. melitensis vjbR::Tn5, in alginate 771 
microspheres [31]. Despite the availability of many experimental Brucella LAV, very 772 
few have been licensed for use due to the caveat of residual virulence and/or reduced 773 
efficacy [27]. To further improve the efficacy of Brucella LAV, strategies that result in 774 
elevated memory cells may be adopted. Elevated T cell immunological memory is a 775 
critical component of vaccine efficacy [125]. The lack of protection, particularly 776 
longevity of protection,  afforded by many vaccines may be attributed to poor induction 777 
of memory cell differentiation. Nowhere is this more evident than in the development of 778 
bacterial subunit vaccines. The failure to identify protective immunogens capable of 779 
inducing demonstrable immunological memory has compelled the continued use of live, 780 
attenuated vaccine candidates with the capacity to deliver antigens for proper immune 781 
stimulation without prolonged persistence or systemic spread that could resulting in 782 
disease. Yet, the use of live, attenuated organisms may also be compromised by the 783 
expression of factors specifically designed to restrict host immunity. Among these gene 784 
products, the TcpB protein, a novel effector for immune evasion [115]. TcpB 785 
accomplishes this action by abbrogating NF-kB  mediated cytokine expression [86] and 786 
inhibiting CD8+ T cell effector function as well as memory cell differentiation. It has 787 
been established that TcpB contributes to T cell memory exhaustion and persistance of 788 
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infection in brucellosis [36]. The mechanism by which TcpB disrupts memory cell 789 
differentiation has been proposed as a disruption of mTOR activation signaling pathway 790 
[36]. Based on these factors, we proposed that a vaccine deficient in TcpB expression 791 
should stimulate enhanced differentiation of memory T cells and confer improved 792 
immunogenicity relative to the parental strain. Because CD4+ T cells  have been 793 
identified as major effectors in Brucella infection, a successful Brucella vaccine is 794 
expected to elicit a robust CD4+ T cell memory differentiation [126]. Minimal attempts 795 
have been made to characterize the longevity and associated ability of Brucella vaccines 796 
to enhance T cell memory differentiation. Determining the presence and quality of long- 797 
lived memory T cells ex vivo may be expected to simplify the processes of vaccine 798 
candidate identification. 799 
In this study, we hypothesized that presence of immune subversive factors play a crucial 800 
role in compromising the safety and efficacy of Brucella LAV. We therefore proposed to 801 
create LAV deficient of immune subversive factor, tcpB, a novel strategy that will 802 
improve their efficacy and safety. 803 
 804 
 805 
 806 
 807 
 808 
 809 
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CHAPTER II 810 
EFFECT OF TCPB DELETION ON IMMUNITY IN BRUCELLA INFECTED 811 
MACROPHAGES 812 
 813 
2.1. Introduction: Immune response to Brucella infection in macrophages 814 
Macrophages are normally activated during infection via pattern recognition by cell 815 
surface proteins including the toll like receptors to stimulate an innate immune response 816 
including expression of proinflammatory cytokines. The cytokines produced during the 817 
early stages of host immune response are essential in defining the type of innate and 818 
subsequent adaptive host immune response to be developed; proinflammatory cytokines 819 
expressed during infection elicit a Th1 immune response [127,128]. Brucella infection 820 
fails to fully activate these pathways based on the weak agonist properties of cell surface 821 
components like non canonical LPS and mechanisms designed to restrict downstream 822 
signaling such as the activity of TcpB [58,88].  In this study, we evaluated the effect of 823 
tcpB deletion on the host’s innate immune responses in macrophages infected with B. 824 
abortus S19. We constructed a tcpB deletion in the wild type strain B melitensis 16M to 825 
create 16MΔtcpB, to determine the effects of tcpB deletion on a fully virulent organism 826 
with fully active immune-suppressive activity. We infected murine macrophages and 827 
studied the resulting replication and immuno-modulatory effects resulting from tcpB 828 
deletion, including the bacterial burden in murine RAW264.7 macrophages over time 829 
and up-regulated expression of proinflammatory cytokines (IL12, TNF and IL6). The 830 
results are consistent with TcpB-mediated suppression of innate immunity and the 831 
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potential to rationally improve Brucella LAVs via removal of similar immune- 832 
suppressive functions. We hypothesized that deletion of tcpB will improve the host 833 
immune response of Brucella LAV (B. abortus S19), and presumably other LAVs as 834 
well. To test this hypothesis, we constructed a ∆tcpB deletion mutant in the Brucella 835 
abortus S19 vaccine strain to create a derivative vaccine S19ΔtcpB.  836 
 837 
2.2 Rationale for the experimentation outlined 838 
Identification and deletion of genes encoding immune subversion factors is a novel 839 
strategy that can be employed to improve vaccine efficacy. Microbial Toll/interleukin 1 840 
receptor proteins are a family of virulence factors that modulate the toll receptor 841 
signaling cascades [33]. Following Brucella infection, TcpB subverts the host’s innate 842 
response by blocking development of immunological memory and altering development 843 
of an adaptive response. TcpB (and/or BtpB) has been shown to abrogate MyD88 844 
mediated NF-κB mediated cytokine gene expression representing novel effectors of 845 
immune evasion. TcpB deletion is expected to maximize high quality T cells that avoid 846 
excessive reduction of T cell subsets after the initial proliferation of early effector T cells 847 
and avoid functional exhaustion during the late phase in order to induce protective 848 
memory. 849 
There is no doubt that innate immune subversion is a primary activity employed by 850 
intracellular pathogens to prevent clearance from the infected host. Among these 851 
mechanisms, TLR2, TLR4, MyD88 are essential for clearance, and by extension the TIR 852 
domain containing proteins reportedly play pivotal roles in preventing clearance by 853 
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impairing the host innate immune response [60]. We propose that removing the genes 854 
encoding TIR domain-containing proteins from Brucella will enhance innate immunity 855 
induced by vaccination. This is built on several observations indicating increased innate 856 
immunity in the absence of these proteins [32]. In line with these observations, we 857 
hypothesized that tcpB deletion in LAV S19 is associated with increased expression of 858 
proinflammatory cytokines and reduction of bacterial burdens in murine macrophages. 859 
We constructed the S19ΔtcpB and B. melitensis 16MΔtcpB mutants and demonstrated 860 
reduced intra-bacterial burdens in infected macrophages. We also hypothesized that this 861 
reduction could be partly associated with cytokine expression induced by S19ΔtcpB and 862 
S19 in murine macrophages. Indeed, we demonstrated elevated cytokine expression in 863 
macrophages infected with the S19ΔtcpB. 864 
 865 
2.3 Materials and methods 866 
2.3.1 Bacterial strains, culture conditions and plasmids for cloning 867 
E. coli strains Top10 DHQ (Invitrogen) were used as hosts for plasmid purification. 868 
E. coli cultures were grown on Luria-Bertani (LB, Difco Laboratories) plates overnight 869 
at 37°C with or without antibiotic supplementation. Antibiotics were obtained from 870 
Sigma-Aldrich® and used at the following concentrations, kanamycin (100 mg/l), 871 
carbenicillin (100 mg/l) or chloramphenicol (50 mg/l). Frozen stocks were prepared in 872 
LB broth supplemented with 50% (v/v) glycerol and stored at -80°C. Various plasmids 873 
were utilized for cloning and electroporation purposes: pKD4 FLP/FRT, KmR, 874 
pEX18ApsacB ApR (the kind gifts of P. Schweizer), pBBR.MCS::CmR (the kind gift of 875 
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M. Roop) and pET His6 Sumo::KanR (Invitrogen™). RAW 264.7 cells (ATCC® TIB- 876 
71™) were cultivated in Dulbeco’s minimum essential media (DMEM) (Life 877 
Technologies) containing 4.5 g/l glucose, 10mM L-glutamine, 10mM sodium pyruvate 878 
and 10% (v/v) fetal bovine serum (FBS) (Life Technologies) in an atmosphere 879 
containing 5% (v/v) CO2 with 100% relative humidity. Passaged cells (n≤15) were 880 
harvested at 90% confluence in T75 flasks, counted and used for infection. 881 
 882 
2.3.2 Construction of Brucella abortus S19ΔtcpB deficient mutant (S19∆tcpB)  883 
The S19∆tcpB mutant was constructed as previously described with minor modifications 884 
[119]. Sequences upstream of the tcpB gene BAbS19_I07080 were amplified from 885 
Brucella abortus S19 genomic DNA using the primer pair 5’- 886 
GGAATTCATTTCGATACGGTGCTGGAC-3’ (upstream EcoRI site) and 5’- 887 
AGCGGCGCGCCATTTGGTCAAGCGTTACCGAC-3’ (downstream AscI site). The 888 
sequence downstream was amplified using the primer pair 5’- 889 
AATGGCGCGCCGCTCCTCACAATACGGGTGT-3’ (upstream AscI site) and 5’- 890 
GGAATTCGGCTGACGACTTTCTCCTTG-3’ (downstream EcoRI site). These two 891 
products were ligated to each other via overlapping PCR placing the AscI site at the 892 
junction of the upstream and downstream fragments. The overlap product was ligated 893 
into pUC9ApR using the unique EcoRI site to create a construct from pEX18AP 894 
containing sites flanking tcpB separated by a unique Asc1 site. Finally, a kanamycin 895 
resistance gene amplified from the plasmid pKD4 (Promega™) was ligated into the 896 
plasmid at the unique AscI site. This new construct was then used for electroporation 897 
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into B. abortus S19 and B. melitensis 16M. Candidate deletion mutants were identified 898 
based on kanamycin resistant growth and carbenicillin sensitivity and verified by PCR 899 
and DNA sequencing, using primers that flank the tcpB locus 5’- 900 
GGAATTCATTTCGATACGGTGCTGGAC-3’ and 901 
GGAATTCGGCTGACGACTTTCTCCTTG-3. The resulting product was then 902 
subjected to electrophoresis. The product was isolated and DNA extracted using a 903 
commercial DNA extraction Kit (Qiagen). The resulting DNA was subjected to a 904 
sequencing cycle on a Thermocyler (Biorad) and run cyc-seq program. (96˚C for 10 sec, 905 
50˚C for 5 sec, 60˚C for 4 min) X 25 cycles then read using a Beckman coulter CEQ-800 906 
genetic analysis DNA system. 907 
 908 
2.3.3 Evaluation of bacterial growth and expression of TcpB 909 
 B. abortus strains S19 and S19∆tcpB from frozen stock were grown on solid media 910 
[tryptic soy broth (TSB) prepared according to the manufacturer’s instructions (BD 911 
Difco™) supplemented with 1.5% (w/v) Bacto-Agar (BD Difco™)]. Colonies from 912 
these plates were used to inoculate TSB. Cultures on solid media or in broth were 913 
incubated up to 72 hours at 37°C. For determination of the growth curve, liquid cultures 914 
were grown to a similar OD, determined using a Klettmeter, equal samples from this 915 
culture were then used to inoculate study cultures. Liquid cultures were agitated 916 
sufficiently to prevent bacteria from forming a pellet. At selected times portions of the 917 
culture were removed and bacterial density determined via serial dilution and plating on 918 
TSA plates. For nucleic acid isolation, portions of the culture were removed and bacteria 919 
 30 
recovered following centrifugation at 5000xg for 5 minutes at 4°C. RNA was extracted 920 
and purified using a commercial kit (Qiagen®) according to the manufacturer’s 921 
instructions. Bacterial cDNA was prepared using primers designed to amplify tcpB 922 
transcripts using RNA to DNA EcoDry™ kit from Clontech®. Briefly, between 1 and 923 
5µg of total RNA was diluted to a final volume of 20µl. Fifty mg of EcoDry premix was 924 
added and the mixture was briefly centrifuged to settle the contents and bring them into 925 
close proximity, prior to incubation for 60 minutes at 42°C. The reaction was stopped by 926 
heating at 70°C for 10 minutes.  927 
 928 
2.3.4  Macrophage infections and survival assay (gentamicin protection assay) 929 
Murine macrophage-like RAW264.7 cells (passage number 4-15) were grown in 930 
Dulbecco's modified Eagle's medium (DMEM) with 10% (v/v) fetal bovine serum, 1 931 
mM L-glutamine, and 1mM nonessential amino acids. 2.5×105 cells were seeded into 932 
each well of a 24-well plate and incubated as described above. The cell monolayers were 933 
infected at a multiplicity of infection (MOI) of 200 CFU per cell unless stated otherwise. 934 
To synchronize the infection, the plates were centrifuged at 250xg for 5 min at room 935 
temperature. Following a 20-min incubation at 37°C, the cells were washed three times 936 
in DMEM medium and incubated for 1 h at 37°C in fresh DMEM supplemented with 937 
100 µg of gentamicin per ml to kill extracellular bacteria. Following a 1 hour incubation, 938 
the monolayers were washed with DMEM to remove gentamicin, followed by cellular 939 
lysis with 0.5 ml of 0.5% (v/v) Tween 20 in sterile water to determine bacterial uptake 940 
(time zero). The colony forming units (CFU) per well were obtained by plating serial 941 
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dilutions on TSA plates with or without supplementation with 100 µg of kanamycin per 942 
ml, as needed. The outcome of bacterial uptake or invasion was presented as the log10 of 943 
the number of bacteria recovered per ml of solution. To assess intracellular growth of the 944 
bacteria, the concentration of gentamicin was reduced to 20 µg/ml and the cultures 945 
incubated up to 72 hours. Infected cells were lysed at selected time points post infection 946 
(p.i), and bacterial recovery determined. All assays were performed in triplicate wells, 947 
and the results represent the average of at least three independent experiments.  948 
 949 
2.3.5 Analysis of cytokine responses from infected macrophages invitro 950 
 Murine macrophage-like RAW264.7 cells were maintained and infected with Brucella 951 
as described in the previous section and supernatants were collected at selected times 952 
post-infection. Briefly, late log phase cultures of Brucella strains S19 and S19∆tcpB 953 
were used to infect the cells at MOIs of 100, and the supernatants harvested from 954 
triplicate wells and stored at -200C. Analysis of cytokine secretion was performed using 955 
ELISA kits from eBiosciencesTM using plates coated with capture antigen at 20µg/ml 956 
(e.g. anti mouse IL12/23 or IL6) in coating buffer (1×PBS) following incubation 957 
overnight at 4°C. The plates were washed (5X) with 0.05% (w/v) Tween 20 in PBS 958 
(PBS-T) and blocked with 1X assay diluent (eBiosciences) for one hour at room 959 
temperature to prevent non-specific binding. Supernatants from the infected and control 960 
cells were added and incubated for two hours at room temperature to allow binding. The 961 
wells were washed as described above and 100µl/well biotin-labeled secondary antibody 962 
was added at 1-2 µg/ml and incubation was continued for one hour. The wells were 963 
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washed, and AVIDIN conjugated HRP added at 0.5-1.0 µg/ml and incubated for a 964 
further one hour. TMB substrate was added and reactivity was characterized following 965 
15 minutes incubation at room temperature after which 50 ul of stop solution was added.  966 
Reactivity was quantified by absorbance at OD450 using an ELISA plate reader 967 
(Multiscan™, Thermolab Systems). Viability of cells was also determined by Cytotox 968 
96® non-radioactive cytotoxicity assay with 90% viability acceptable (Promega). 969 
 970 
2.3.6 Cloning and expression of histidine-tagged TcpB 971 
S19 cultures were grown to log phase, at which point they were inactivated by 972 
incubation at 68°C for 24 hours. The cells were pelleted and genomic DNA extracted 973 
using Qiagen® DNA isolation kit as per the manufacturer’s instructions. TcpB specific 974 
primers (ATG TCT AAA GAG AAA CAA GCC and GAT AAG GGA ATG CAG TTC 975 
TTT CGC) were used to amplify the tcpB open reading frame (ORF). The amplified 976 
product was cloned into the plasmid pET-SumoHis to generate the construct pETSumo- 977 
TcpB. Cloning of the tcpB ORF was validated by DNA sequencing, and the plasmid was 978 
then used to transform E. coli BL21 (DE3) cells (Invitrogen™). The transformed BL21 979 
cells were transferred and grown LB supplemented with antibiotic when appropriate and 980 
1 mM glucose, and expression was induced at log phase by the addition of IPTG 981 
(Thermo Fisher Scientific) to a final concentration of 1mM.  Following incubation for an 982 
additional 3 hours at 37°C, the bacteria were pelleted by centrifugation for 20 minutes at 983 
5000xg and the pellets were resuspended and lysed in 2×SDS. The denatured proteins 984 
were separated by electrophoresis on 12.5% (w/v) SDS-PAGE gels. The gels were 985 
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stained with 0.25% (w/v) Coomassie blue R-250 for 2 - 4 hours until the gel was a 986 
uniform blue color (Sigma-Aldrich®) and then destained in water.  Expression of TcpB 987 
was confirmed via Western blotting as described below. 988 
 989 
2.3.7 Purification of his-tagged TcpB 990 
The expressed TcpB-sumo protein was purified using native conditions by the 991 
ProBond™ purification system according to the manufacturer’s instructions (Life 992 
Technologies™). Briefly, cells were harvested from a 50 ml culture prepared as 993 
described in the previous section via centrifugation at 3000xg for 10 minutes in a Sorvall 994 
RC 6 C centrifuge rotor. The pellet was re-suspended in 8 ml native binding buffer (50 995 
mM NaHPO4 and 0.5 M NaCl) supplemented with 1mg/ml of lysozyme and incubated 996 
on ice for 30 minutes.  The cells were then lysed on ice via sonication (with a Cole 997 
Palmer Ultrasonic processor Model GEX130) using six 10-second bursts at high 998 
intensity with a 10-second cooling period between each burst.  The lysate was 999 
centrifuged at 3000×g for 15 minutes to pellet the cellular debris. His-tagged TcpB was 1000 
purified from the lysate using nickel chelating resin (Invitrogen) according to the 1001 
manufacturers instructions. Briefly, the lysate was gently agitated with a nickel chelating 1002 
resin after which the resin was allowed to settle by gravity or centrifugation at 800×g for 1003 
1 minute. Native wash buffer was then used to remove unbound protein in a series of 1004 
five washes. The resin was then poured into a resin-column (InvitrogenTM) clamped in a 1005 
vertical position and bound protein eluted using native elution buffer (50mM NaH2PO4, 1006 
0.5M NaCl and 250mM Imidazole). The eluted protein was subjected to SDS PAGE 1007 
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electrophoresis and stained with coomassie blue (Sigma-Aldrich) and subjected to 1008 
western blot analysis.  The eluted protein was stored at -20°C until needed for use. 1009 
 1010 
2.3.8 Western blots for detection of his-tagged protein 1011 
Following purification of the protein, it was subjected to SDS-PAGE gel electrophoresis 1012 
after which the protein was transferred to a PVDF membrane (Millipore). The membrane  1013 
was blocked using blocking buffer  (5% skimmed milk in 1XPBS) overnight at 4°C. The 1014 
membrane was then washed 3 times in wash buffer (0.5% Tween 1XPBS), 5 minutes 1015 
each. The membrane was then incubated with a 1:1000 dilution of mouse anti histidine 1016 
antibody (Sigma-Aldrich) in 1% blocking solution overnight at 4°C. The membrane was 1017 
then washed three times, 5 minutes each. The membrane was incubated with a 1:5000 1018 
dilution of secondary antibody HRPO-conjugated rabbit anti mouse IgG (Sigma- 1019 
Aldrich) in 5% blocking buffer in TBST at room temperature for 1 hour. The membrane 1020 
was then washed three times. For signal development the membrane was incubated in 5 1021 
ml of HRP-chemiluminescent substrate (Denville Scientific) Excess reagent was 1022 
removed and the membrane covered in transparent plastic wrap. The signal was acquired 1023 
using darkroom development techniques for chemiluminesence. 1024 
 1025 
2.3.9 Removal of endotoxins from expressed proteins 1026 
Endotoxins were removed from expressed proteins using the proteospin endotoxin 1027 
removal kit (Norgen, Biotek, CA) according to the manufacturers instructions described 1028 
as follows. Briefly, the expressed protein sample was diluted to a final volume of 450 µL 1029 
 35 
using sterile, deionized water. 20 µL of Binding Buffer was added to the protein and the 1030 
pH of the resulting solution was adjusted to 3.5 by addition of 2N HCl. The endotoxin 1031 
binding column was then activated by adding the provided activating solution. The 1032 
protein sample was then transferred to the activated column and a 1% volume of 1033 
endotoxin removal solution added. The column was mixed gently by inversion and 1034 
allowed to stand for 5 minutes following which 1/10th volume of isopropanol was added. 1035 
Following centrifugation at 14,000xg for 1 minute, the protein was eluted into 9.3µl of 1036 
neutralizer solution in an elution tube by centrifugation at 14,000xg for 1 minute. The 1037 
absence of endotoxin was confirmed using Toxin-SensorTM Chromogenic LAL 1038 
Endotoxin Assay Kit (Genscript, Scotch Plains, NJ) 1039 
 1040 
2.3.10 Determination of uptake of TcpB by RAW264.7 cells 1041 
 RAW 264.7 cells (1×105) in DMEM media were seeded into each well of 24 well plates 1042 
and incubated for 24 hours at 37°C. The DMEM media was replaced with media 1043 
supplemented with 50µg/ml of His tagged protein and the plates were then incubated at 1044 
37°C for 2, 5, 24, 48 and 72 hours. At the specified time points, culture media was 1045 
aspirated, and the wells were rinsed 5 times with PBS. Adherent cells were harvested 1046 
into the same solution by scraping and the cell suspension transferred to 1 ml tubes and 1047 
centrifuged to collect the cells. Cells were lysed with 2×SDS-PAGE sample buffer and 1048 
proteins resolved on SDS PAGE gel in the presence of His tagged-TcpB via Western 1049 
analysis using anti-His antibody conjugated with HRP as described above 1050 
 1051 
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2.3.11 Complementation of the tcpB mutation 1052 
To complement the tcpB defect, the His-tagged protein was purified using a nickel 1053 
column system as described above (section 2.3.9). The concentration of the purified 1054 
protein was determined using the Bradford assay [129]. TcpB protein was added to 1055 
RAW264.7 cells growth medium at a final concentration of 50 ug/ml and uptake of the 1056 
protein was monitored as originally described by Radhakrishnan et al. [35]. The cells 1057 
were washed 5 times with 1×PBS following which they were lysed with 2×SDS buffer. 1058 
The samples were subjected to electrophoresis via SDS-PAGE and the separated 1059 
proteins were transferred to PVDF membrane and probed using mouse anti-His antibody 1060 
as described above. Cells were pre-incubated with the protein prior to infection with the 1061 
B. abortus ΔtcpB mutant; the effect on replication was determined using the gentamicin 1062 
protection assay described previously. 1063 
 1064 
2.3.12 Determination of viability of cells (cytotoxicity assay)(Promega) 1065 
Supernatants were collected from experimental wells in the assays from the 24 wells 1066 
plates and stored at -200C until ready for use. Lactate dehydrogenase (LDH) levels in the 1067 
medium were measured using the cytotox 96 LDH kit (Promega) according to the 1068 
manufacturer’s instructions. Briefly, supernatants were equilibrated at room temperature 1069 
and 100 ul added to wells in a 96 well microtiter plate. The provided cytotox 96 reagents 1070 
was then prepared and added at 1:1 to the cell culture supernatants. The assay plate was 1071 
incubated for 30 minutes at room temperature protected from light. 50ul of stop solution 1072 
was then added to each well of the plate. The absorbance was read at 430nm. The 1073 
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percentage cytotoxicity was determined as percentage experimental LDH release 1074 
release/Maximum LDH release. Maximum release was determined by addition of LDH 1075 
lysis reagent provided in the kit. 1076 
 1077 
2.4  Statistical analysis 1078 
Bacterial burdens in cell culture were expressed as log 10 CFU/ml +/- standard deviation 1079 
(SD). Immune responses of infected cells were expressed in the form of cytokine 1080 
concentration were obtained by plotting ODs against concentrations obtained from kit 1081 
standards. Concentrations were then plotted against time post inoculation.  Statistical 1082 
comparisons between groups was done by use a two way ANOVA followed by a 1083 
Student’s t test to determine the statistical validity of observed differences between 1084 
experimental data sets. P values ≤0.05 were considered to be significant. 1085 
 1086 
2.5  Results 1087 
2.5.1 Construction of S19ΔtcpB and B. melitensis 16MΔtcpB deletion mutants 1088 
Primers were designed to amplify a 500bp region flanking the tcpB gene on the 5’ end 1089 
and a 300bp region flanking the tcpB gene on the 3’ end. The two segments were then 1090 
joined in an overlap extension PCR with adjoining AscI restriction site between the 1091 
fragments. The resulting PCR product was ligated into the pEX18Ap plasmid. A 1092 
kanamycin resistance cassette was amplified from a plasmid pKD4 and inserted into the 1093 
AscI site. The resulting construct was electoporated into S19 and homologous 1094 
recombination between the genome and the plasmid-encoded ∆tcpB (Km) results in the 1095 
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replacement of tcpB gene.  The mutants were identified by resistance to kanamycin and 1096 
sensitivity to ampicillin, i.e., exclusion of co-integrates and designated as Brucella 1097 
abortus S19 ΔtcpB(Km) or S19ΔtcpB(Km) (see Fig. 1) 1098 
 1099 
 1100 
 1101 
 1102 
 1103 
Fig. 1.  Schematic representation of the method of construction of tcpB mutant strains. 1104 
Two fragments flanking the tcpB gene were amplified in the first round of PCR using 1105 
primers F1, R1 and F2, R2 with EcoR1 and Asc1 unique restriction sites as shown on the 1106 
diagram. The fragments were then joined in the second round of overlap extension PCR, 1107 
creating a unique Asc1 restriction site. The resulting product was cloned into the plasmid 1108 
pEX18AP and a kanamycin resistance cassette was inserted between the two PCR 1109 
fragments, and the resulting product used to electroporate B. abortus S19 and B. 1110 
melitensis 16M. Marked mutants B. melitesis ΔtcpB:Kan and B. melitensisΔtcpB:Kan 1111 
were formed by homologous recombination 1112 
 1113 
 1114 
 1115 
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2.5.2 Validation of the ΔtcpB deletion 1116 
 Primers were designed to amplify a region encompassing the 700 bp region at the 5’ end 1117 
of the tcpB locus and a 500 bp region at the 3’ end. PCR amplification of the template 1118 
from the ΔtcpB mutant yielded a 2.8 kb fragment due to the insertion of a 1.5 kb 1119 
kanamycin cassette in addition to the flanking fragments. Amplification of the DNA 1120 
template from S19 yielded a smaller 1.8 kb fragment. The two fragments were then 1121 
sequenced to confirm deletion of tcpB observed (see Fig. 2 & 3) 1122 
 1123 
 1124 
 1125 
 1126 
Fig. 2.  PCR validation of S19ΔtcpB mutants. PCR products from genomic DNA 1127 
extracted from Brucella strains S19, S19ΔvjbR, and S19ΔtcpB were amplified with 1128 
primers flanking the tcpB gene. (S19ΔvjbR was created by deletion of the vjbR gene 1129 
[119]). Lower panel, Genetic map of B. abortus S19, showing the location of the tcpB 1130 
gene (S19_I07090) and the neighboring genes. To create the mutants, a kanamycin 1131 
cassette (Kan 1.5 kb) displaced the tcpB (tcpB 753 bp) gene by homologous 1132 
recombination as indicated in the diagram. 1133 
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Fig. 3 a). Sequences of 3’junction between tcpB mutants and kanamycin cassette in B. 1141 
abortus S19. S19ΔtcpB genomic DNA showing the 3’ junction of insertion of 1142 
Kanamycin resistance cassette (pKD4).  PCR products for S19ΔtcpB and 16MΔtcpB 1143 
were cut from the gel and DNA extracted using a commercial kit  (Qiagen). Specific 1144 
primers were used to sequence the extracted DNA and data acquired using a Beckman 1145 
coulter CEQ-800 genetic analysis DNA system. 1146 
 1147 
 1148 
 1149 
S19_I7110 
pKD4 
a) 
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Fig. 3 b) Sequences of 3’junction between tcpB mutants and kanamycin cassette in B. 1154 
melitensis 16MΔtcpB. B. melitensis 16MΔtcpB genomic DNA showing the 3’ junction of 1155 
insertion of Kanamycin resistance cassette (pKD4).  PCR products for S19ΔtcpB and 1156 
16MΔtcpB were cut from the gel and DNA extracted using a commercial kit  (Qiagen). 1157 
Specific primers were used to sequence the extracted DNA and data acquired using a 1158 
Beckman coulter CEQ-800 genetic analysis DNA. 1159 
  1160 
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 1171 
1 TCTATTCGGC TCGATTGCGC AGATGCATGA ACGTGTACTG
41 GATGGATGTC GTAAGCGGTT GATGAATGGA TTGCTCACAC
81 CGGCGTTTGT TCGTGCGCGT ATCGATGCAC TGGAAAAGTC
121 GCAGCCCTCT CTCGGAGGCG CTTCCCATGT TCGATAAGCT
161 GACAAGCCCG CATGAAGGTT TTCGTCTCGC TGACCTTTCA
201 CGCCGTCAAT GCAAGTGGCC CGTCAATCGT GCGCAAGCTG
241 GAGAGCTTCA TCTGTTCTGT GGCGAGGCTG TCCAAAATGG
281 ACACCCGTAT TGTGAGGAGC GGCGCGCCCA CGTCTTGAGC
321 GATTGTGTAG GCTGGAGCTG CTTCGAAGTT CCTATACTTT
361 CTAGAGAATA GGAACTTCGG AATAGGAACT TCAAGATCCC
401 CCACGCTGCC GCAAGCACTC AGGGCGCAAG GGCTGCTAAA
441 GGAAGCGGAA CACGTAGAAA GCCAGTCCGC AGAAACGGTG
481 CTGACCCCGG ATGAATGTCA GCTACTGGGC TATCTGGACA
521 AGGGAAAACG CAAGCGCAAA GAGAAAGCAG GTAGCTTGCA
561 GTGGGCTTAC ATGGCGATAG CTAGACTGGG CGGTTTTATG
601 GACAGCAAGC GAACCGGAAT TGCCAGCTGG GGCGCCCTCT
641 GGTAAGGTTG GGAAGCCCTG CAAAGTAAAC TGGATGGCTT
681 TCTTGCCGCC AAGGATCTGA TGGCGCAGGG GATCAAGATC
721 TGATCAAGAG ACAGGATGAG GATCGTTTCG CATGATTGAA
761 CAAGATGGAT TGCACGCAGG TTCTCCCGGC CGCTTGGGTG
801 GAGAGGCTAT TTCGGCTATG ACTGGGCACA ACAGACAATC
841 GGCTGCTCTG ATGCCCGCCG TGTTCCGGCT GTCAGCGCAG
881 GGGCGCCCCG GTTTCTTTTT TGTCAAGACC GACCTGTCCG
921 GTGCCCTGAA TGAACTTGCA GGAACGAGGC ATCGCGGCTA
961 TTCGTGGGCT GGGCCACAAA GGGC
BMEI1675 
pKD4 
b) 
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2.5.3 Growth of S19, S19ΔtcpB, B. melitensis 16M and 16MΔtcpB in TSB media 1172 
 Replication of S19ΔtcpB and S19 was characterized as normal sigmoidal growth curves 1173 
with defined lag, log and plateau phases indistinguishable from the parental strain. It was 1174 
therefore concluded that deletion of tcpB had no effect on replication of the organism 1175 
outside of the host under the conditions described (Fig. 4). 1176 
 1177 
 1178 
 1179 
 1180 
 1181 
 1182 
Fig. 4 a). Growth of Brucella melitensis (16M and 16MΔtcpB) strains TSB media. 1183 
 B. melitensis 16M and B. melitensis 16MΔtcpB in rich culture media (TSB). 5 ml of 1184 
TSB media were inoculated with equal cultures of B. abortus S19 and S19ΔtcpB or 1185 
B. melitensis 16M and B melitensis 16MΔtcpB, and at specified intervals, samples were 1186 
collected from the cultures and platted on TSA plates. The plates were incubated for 3 1187 
days at 370C, after which the colonies were counted and documented The cultures were 1188 
grown until late plateau phase at which point culture viability was on the decline. Results 1189 
shown are one of three independent experiments. Bacterial loads are expressed as Log 1190 
10CFU/ml +/-SD. 1191 
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Figure 4 b) Growth of Brucella abortus (S19 and S19ΔtcpB) strains in TSB media.  B. 1197 
abortus S19 and S19ΔtcpB and in rich culture media (TSB). 5 ml of TSB media were 1198 
inoculated with equal cultures of B. abortus S19 and S19ΔtcpB or B. melitensis 16M and 1199 
B melitensis 16MΔtcpB, and at specified intervals, samples were collected from the 1200 
cultures and platted on TSA plates. The plates were incubated for 3 days at 370C, after 1201 
which the colonies were counted and documented The cultures were grown until late 1202 
plateau phase at which point culture viability was on the decline. Results shown are one 1203 
of three independent experiments. Bacterial loads are expressed as Log 10CFU/ml +/-SD.  1204 
 1205 
 1206 
2.5.4 Cloning, expression and purification of his-tagged TcpB 1207 
For complementation studies, tcpB was cloned and expressed from the plasmid pET 1208 
SUMO (Champion™, Life Technologies®). SUMO-CAT was used an expression 1209 
control. Primers were designed and used to amplify the full ORF of tcpB from S19 1210 
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genomic DNA (see section 2.2.8). The PCR product was then cloned into pET SUMO to 1211 
create pET SUMO-tcpB. The plasmid was then used to transform BL21 cells. The cells 1212 
were grown in LB medium and induced by the addition of IPTG. The proteins were 1213 
purified, expressed and analyzed as described materials and methods (Fig 5).  1214 
 1215 
 1216 
 1217 
a)  1218 
 b)   1219 
Fig. 5. Cloning and expression of TcpB. a) SDS PAGE gel images of coomassie blue 1220 
stain of TcpB at various times of induction. Lanes 1 (ladder) 0, 2, 3 and 4 induced 1221 
lysates at 0, 2, 3 and 4 hours respectively.  b) Western blots stain for TcpB-sumo (lane 1) 1222 
and Sumo-CAT (lane 2).  1223 
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2.5.5 Uptake of TcpB by RAW 264.7 cells 1225 
The structure of TcpB depicts an N terminus with a basic amino acid rich lipid-binding 1226 
domain and the C-terminus encodes a TIR domain (Fig. 6a) [35]. TcpB harbors 1227 
endogenous cationic motifs conferring cell permeable properties. The cationic amino 1228 
acid residues bind to the cell surface trapping the protein, and the protein is then taken 1229 
up by the cellular endocytic pathway (Fig 6b) [35]. In this study, we sought to analyze 1230 
the internalization of His-tagged TcpB by RAW264.7 cells. Murine macrophages were 1231 
incubated with purified with His-tagged TcpB at a final concentration of 50µg/ml and 1232 
verified the translocation of TcpB was verified by western blotting. Sumo-TcpB could be 1233 
located in the cell, while internalization was not observed in cells incubated with the  1234 
Sumo-CAT control protein indicating that the cell permeable property is attributed to 1235 
TcpB (Fig 7). Sumoylation is needed for proteins to enter stable complexes or functional 1236 
states enhancing solubility and expression, but is dispensable after the initial 1237 
establishment [130]. 1238 
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Fig. 6. Schematic representation and protein sequence of TcpB. 1267 
a) Schematic representation of the Brucella tcpB protein showing the position of the TIR 1268 
domain, TIR boxes and the lipid binding domain. b) Protein sequence of TcpB showing 1269 
the location of basic amino acids (Lysine, arginine, histidine) (blue) and the TIR 1270 
domains (red)  1271 
 1272 
 1273 
 1274 
TIR$domain$
Bo
x$
1$
Bo
x$
2$
Bo
x$
3$
Basic$amino$acid$rich$
Lipid$binding$domain$
 47 
 1275 
 1276 
Fig. 7.  Uptake of TcpB By RAW264.7 macrophages.  1277 
Western blot analysis of RAW264.7 cells pre-incubated with purified TcpB-Sumo or 1278 
Sumo. Raw264.7 cells were incubated with 50 µg/ml of tcpB-sumo or Sumo-CAT and 1279 
samples collected at various time points as described in materials and methods. The 1280 
samples were subjected to Western blot analysis using mouse anti-His antibody. 1281 
 1282 
 1283 
2.5.6 The effect of tcpB deletion on intramacrophage burden of Brucella 1284 
Previous studies have indicated that Brucella ∆tcpB mutants exhibit little change in 1285 
intracellular survival relative to the parental organism. However, a proposed ∆tcpB 1286 
deletion from Brucella abortus S19 vaccine may offer an opportunity to enhance overall 1287 
immune protection in a genetic background associated with reduced virulence, safety 1288 
and genetic stability. To determine the effect of the tcpB deletion on the virulence of 1289 
S19, the rate of growth of the mutant relative to the parent strain was evaluated in vitro 1290 
in the murine leukemic monocyte-derived macrophage cell line RAW264.7. The cells 1291 
were infected with either parental S19, or the S19ΔtcpB mutant, and the parental B. 1292 
melitensis 16M or the 16M∆tcpB mutant, and evaluated for the rate of replication and 1293 
intramacrophage bacterial burdens evaluated at defined time points. For 1294 
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complementation studies, the RAW264.7 cells were pre incubated with 50µg/ml of 1295 
purified TcpB for 24 hours.  No significant differences in invasion or intracellular 1296 
replication were noted between S19 and S19ΔtcpB mutant at 24 hours post infection. 1297 
However, there were reduced bacterial burdens in macrophages infected with the mutant 1298 
strains at 48 hours and 72 hours post infection (p<0.05). Similarly 16M∆tcpB showed 1299 
reduced intramacrophage burdens at 24, 48 and 72 hours post infection (see Fig 8) 1300 
(p<0.05). 1301 
 1302 
 1303 
 1304 
 1305 
 1306 
 1307 
 1308 
 1309 
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Fig. 8. Evaluation of replication and intramacrophage burden of Brucella strains.  a) 1312 
S19 and S19ΔtcpB. b) Brucella melitensis 16M and 16MΔtcpB. RAW264.7 cells 1313 
were infected with S19 or S19ΔtcpB or B.m16MΔtcpB. Bacteria burdens were 1314 
determined by lysis with 0.5% (v/v) Tween 20 in water and plated on TSA plates. For 1315 
complementation studies, RAW264.7 cells were pre-treated for 24 hours with TcpB 1316 
protein at a concentration of 50 µg/ml prior to infection. All experiments were done 1317 
in triplicate and results are a representation of three independent experiments. 1318 
Bacterial burdens were represented as the mean Log10CFU/ml ±SD. Differences 1319 
between groups were determined by analysis of variance (ANOVA) using Prism 1320 
software (GraphPad). A p value <0.05 was considered statistically significant. 1321 
 1322 
 1323 
 1324 
2.5.7  Cytotoxicity of RAW264.7 cells infected with Brucella strains 1325 
RAW264.7 cells infected with S19 or S19ΔtcpB were monitored for cytotoxicity by the 1326 
cytotox96® non-radioactive cytotoxicity assay (Promega). While the cells manifested a 1327 
cytotoxity of between 5-15% over the period of the experiment, there was no significant 1328 
difference observed in cytotoxicity between cells infected by either S19 or S19ΔtcpB 1329 
(Fig. 9). 1330 
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Fig. 9. LDH release by RAW264.7 cells infected with S19 or S19ΔtcpB. 1334 
Supernatants were collected from RAW264.7 cells infected with S19, S19ΔtcpB and  1335 
S19ΔtcpB+TcpB. Cytotox96 non-radioactive assay was used to determine the levels of 1336 
 LDH released by the cells. ODs were measured at 530nm and % cytotoxicity calculated 1337 
 as LDH release release/Maximum LDH release.  Percent cytotoxicity is expressed as  1338 
mean of three results ±SD.  1339 
 1340 
 1341 
2.5.8 tcpB deletion enhances proinflammatory cytokine production in macrophages in 1342 
culture 1343 
Brucella ∆tcpB mutants induced increased cytokine production (IL-1ß and TNFα) 1344 
relative to the parental organism in IRF-/- mice [86]. To characterize cytokine 1345 
production, RAW264.7 cells were infected with S19 and S19∆tcpB at an MOI of 100. 1346 
Supernatants were collected from the infected monolayers and sandwich ELISA was 1347 
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performed to quantify cytokine expression. Consistent with the prediction based on the 1348 
enhanced translocation of NF-κB and AK-1 activity, macrophages infected with 1349 
S19ΔtcpB exhibited significantly elevated IL12 p40 at 72 hours and IL6 cytokine 1350 
production at 48 and 72 hours in comparison to those infected with S19 and uninfected 1351 
controls as shown in Fig. 10. 1352 
 1353 
 1354 
 1355 
 1356 
 1357 
Fig .10. Expression of cytokines by RAW264.7 cells infected with Brucella strains. 1358 
 a) IL-12p40 and b) IL 6 by RAW 264.7 macrophages infected with S19 or S19ΔtcpB. 1359 
Culture supernatants were collected and analyzed for the presence of IL-12p40 via 1360 
sandwich ELISA. Data represent one of three independent experiments. Concentration 1361 
levels are cytokine concentrations expressed as the mean pg/ml±SD plotted over time for 1362 
each group. A p value <0.05 is considered significant. The significance differences 1363 
between groups were determined by analysis of variance (ANOVA) using Prism  1364 
software (GraphPad).  1365 
 1366 
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Fig. 10 continued 1368 
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 1371 
2.6 Discussion 1372 
Brucella invades and replicates in cells of the reticuloendothelial system, especially 1373 
macrophages, dendritic cells and placental trophoblasts. Resistance to killing 1374 
mechanisms expressed by these host cells has been suggested to be the factor controlling 1375 
Brucella invasion, survival, persistence and virulence in the infected host. Generally 1376 
referred to as a stealth pathogen, the Brucella elicits a weak innate immune response 1377 
derived in part from the poor activation of Toll like receptor pathways. Additional 1378 
mechanisms include expression of effectors that subvert downstream pathways to reduce 1379 
the innate immune response. One such factor is the Toll interleukin receptor (TIR) 1380 
domain containing protein TcpB. Based of the published evidence of immune 1381 
subversion, the tcpB gene was chosen as target of interest for deletion in a rational 1382 
approach to improve Brucella LAV. TcpB expression by Brucella has been suggested to 1383 
abrogate TLR mediated MyD88 signaling thus limiting the host innate and subsequent 1384 
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adaptive immunity that is essential in the control of brucellosis. In our experiments, 1385 
constructed the tcpB mutant in S19 and B. melitensis 16M, we then evaluated the role of 1386 
tcpB in Brucella infection, survival and replication in RAW264.7.  Our experiments 1387 
have shown that deletion of tcpB does not affect the growth rate of Brucella TSB media, 1388 
indicating that the cultural characteristics of Brucella following tcpB deletion are 1389 
unchanged outside the host (Fig 4).  The results of intramacrophage replication however 1390 
showed reduced bacterial burden of the mutant organism at about 48 and 72 hours post 1391 
infection (Fig 9). We concluded that reduction in intramacrophage burdens was due to 1392 
the interaction between tcpB and the host factors. We further examined the effect of 1393 
tcpB mutation on Brucella induced host expression of proinflammatory cytokines (IL12 1394 
and IL6). It is therefore concluded that deletion of tcpB deletion is associated with 1395 
increased proinflammatory activity, a mechanism that is proposed to enhance 1396 
macrophage killing and reduced survival of Brucella as manifested by a reduction in 1397 
bacterial burden. Interleukin 12 stimulates intracellular expression of IFN-γ by 1398 
macrophages and dendritic cells via activity of transducer and activator of transcription 4 1399 
(STAT4) skewing the macrophage function toward the M1 phenotype [131]. M1 1400 
macrophages are characterized by increased microbicidal activity, due to secretion of 1401 
high levels of pro-inflammatory cytokines such as TNFα and IL-6, production of 1402 
reactive oxygen intermediates (ROI) and nitric oxide synthase-2 (NOS-2/iNOS), high 1403 
antigen-presenting activity and increased production of IL-12 [132]. As the strong T-cell 1404 
stimulating potential of the smooth attenuated B. abortus S19 in vivo has been 1405 
documented before [133], we were interested in the possible exploitation of this 1406 
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mechanism to enhance its vaccine potential. We hypothesized that increased 1407 
inflammation may be exploited in the design of more effective Brucella vaccines. We 1408 
exploited the immune upregulating role of a tcpB deletion to design a vaccine with 1409 
higher efficacy. This study alone supports the possibility that a rationally designed 1410 
Brucella vaccine may enhance the proinflammatory response to provide an adjuvant 1411 
effect producing Th1 cytokines that drive the activation of effector and memory T cells.  1412 
We also propose that a drawback to this increased proinflammatory response is the 1413 
potential for enhanced pathology such as splenomegaly and will require additional 1414 
animal trials to reconcile. 1415 
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CHAPTER III 1427 
TCPB DELETION CONFERS IMPROVED IMMUNOGENICITY AND 1428 
PROTECTIVE EFFICACY TO BRUCELLA ABORTUS S19 (S19) 1429 
 1430 
3.1 Introduction 1431 
Brucella melitensis, B. abortus and B. suis are the three main etiological agents for 1432 
human brucellosis. Their preferred natural hosts are sheep and goats, cattle, and swine, 1433 
respectively [134.]. Although, live attenuated vaccines (LAVs) provide the best 1434 
protection against challenge, their use is restricted due to several side effects including 1435 
residual human virulence, and abortion in ruminants posing direct threats to public 1436 
health [135,136]. Several Brucella strains have been attenuated and used as improved 1437 
vaccines with varying immunogenicity and safety.  S19, a spontaneously occurring 1438 
attenuated form of B. abortus, has been used in the control of brucellosis in the U.S. and 1439 
other parts of the world [137]. S19 is the vaccine of choice for the introduction of 1440 
genetic attenuating mutations to enhance safety and reduce residual virulence for use in 1441 
animals and to limit human exposure. This is supported by: i) previous evaluation in 1442 
humans, ii) genetic stability in a wide variety of hosts, iii) cross protection against 1443 
B. melitensis, the most prevalent cause of human brucellosis, and iv) greatly reduced 1444 
human virulence [3,138-140]. Similarities in immune response with wild type strains 1445 
also prevent differentiation of infected animals from S19 vaccinated animals (DIVA). To 1446 
further improve the safety and efficacy of S19, the vaccine has been genetically 1447 
modified by identifying and deleting virulence genes to provide vaccine strains with 1448 
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significant immunogenic activity and enhanced protective efficacy while protecting the 1449 
health and safety of the target species and the public [31,141]. Brucella TIR proteins 1450 
bear significant homology to mammalian TIR [33,142]. Two TIR domain-containing 1451 
proteins, TcpB/Btp1 and Btp2 have been identified in Brucella spp. [32,33]. TcpB has 1452 
been shown to inhibit TLR2 and 4 mediated activity in HEK293 cells, and to bind to and 1453 
promote the degradation of TIRAP resulting in abrogation of NF-kB mediated 1454 
expression of proinflammatory cytokines [115]. This was validated in an experiment in 1455 
which the secretion of TNF-α and IL-12p40 by bone marrow derived dendritic cells was 1456 
impaired upon infection with wild type B. abortus in comparison with TcpB deficient 1457 
strain [115]. Subcellular localization studies have indicated that TcpB co-localizes with 1458 
the plasma membrane and microtubules by binding to phosphoinositides [PI (4,5)P2] 1459 
[86]. It has been proposed that the binding of TcpB to PI (4,5)P2 leads to a disruption of 1460 
the action of the mTOR signaling pathway which limits effector CD8+T and CD4+T cell 1461 
transition to long lived memory T cells [31,75]. As a result, infection with virulent 1462 
Brucella has been proposed to restrict the number of T cells differentiating into memory 1463 
cells, resulting in a lack of protective memory and reduced immune protection [36]. 1464 
TcpB plays an important role in reducing the Brucella induced secretion of cytokines as 1465 
we have shown in our prior in vitro experiments in which proinflammatory cytokines 1466 
(IL6 and IL12) were elevated levels in macrophages infected with TcpB deficient strains 1467 
of B. abortus S19. This agrees with an experiment in which cytokine profiles showed 1468 
elevated levels of IL-1ß and TNFα in IRF-/- mice infected with a TcpB deficient strain of 1469 
Brucella [86].  As a proinflammatory cytokine, TNF-α drives secretion of IL-12 and 1470 
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IFNγ by dendritic cells and macrophages, directing an acquired secondary response of 1471 
the Th1 phenotype by CD4+ and a Tc 1 phenotype by CD8+ lymphocytes [143]. The Th1 1472 
immune response against Brucella leads to IFNγ secretion by antigen-speciﬁc T 1473 
lymphocytes mostly CD4+T cells which have been shown to be the major producers of 1474 
IFNγ [144]. IFNγ also activates the bactericidal action of macrophages, expression of 1475 
antigen presenting and co-stimulatory molecules on antigen presenting cells, CTL 1476 
mediated cytotoxicity, and potentiates apoptotic death of infected macrophages [145] 1477 
(Fig 9). Recent data obtained in IFNγ and IL-12/β2-microglobulin knockout mice 1478 
demonstrate that the lack of endogenous IFNγ is more important to the control of 1479 
brucellosis than CTLs [126]. This underscores the crucial roles played by IFN-γ 1480 
producing CD4+ T cells in the control of brucellosis. However, in chronic brucellosis T 1481 
cells display an immune deficit that is associated with TcpB, which inhibits CTL killing 1482 
and memory T cell differentiation, constituting a novel effector of immune evasion [75]. 1483 
TcpB has also been associated with increased endoplasmic reticulum (ER) stress. TcpB, 1484 
however, inhibits MyD88 mediated ER stress by abrogating the XBP-1 splicing, causing 1485 
reduced cytokine expression [44]. TcpB-deficient B. melitensis mutants have been 1486 
observed to have deficient dissemination in IRF-/- mice [75]. In this study, we 1487 
hypothesize that deletion of TcpB in the live attenuated vaccine, B. abortus S19, will 1488 
improve innate as well as adaptive immunity resulting into enhanced protective efficacy. 1489 
On vaccination, Brucella LAV are phagocytized by macrophages and dendritic cells 1490 
where they are contained in the BCV [146].  B. abortus S19 activates the TLRs of the 1491 
phagocytizing cells and causes induction of proinflammatory cytokines expression of 1492 
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IL6 and IL12 [147].   IL12 acts on Th0 cells causing them to differentiate into Th1 cells 1493 
that are crucial for expression of IFNγ [148].  IFNγ then activates intramacrophage 1494 
killing of Brucella in addition to activating the cytotoxic activity of CD8 T cells [149]. 1495 
Antigen presentation by infected macrophages to CD4+ T cells in the context of MHC 1496 
class II also leads to activation, differentiation, and subsequent effector functions 1497 
including expression of IL2 that leads to clonal expansion of CD4+ and CD8+ T cells. 1498 
IL6 produced by activated macrophages acts on regulatory T cells (T regs) suppressing 1499 
their expression of Th2 cytokines [150]. The net result of vaccination with B. abortus 1500 
S19 is up regulation of the Th1 response, (fig 11), a feature that is lacking in wild type 1501 
Brucella that are responsible for activation of lowered Th1 phenotype and persistence of 1502 
infection.  1503 
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Fig. 11. Immunity in Brucella vaccination. Following vaccination, Brucella abortus S19 1506 
(red rectangles) are phagocytized by macrophages or other antigen presenting cells. 1507 
Brucella are maintained in BCV where they replicate and avoid lyosomal degradation. 1508 
Infected APCs traffic to the local LN where, Brucella antigens are processed and 1509 
antigens are presented to naïve T cells in the context of MHC class II. The activated 1510 
APCs produce IL-12 that skews the T cell phenotype to Th1. The Th1 cells then produce 1511 
IFN-γ that activates macrophages to kill intracellular bacteria. IFNγ also activates the 1512 
cytotoxic activity of CD8+ T cells, which kill infected cells that present antigens in the 1513 
context of MHC class I. IFN-γ produced by Th1 cells also down regulate Th2 cells. 1514 
Activated macrophages also express IL-6, a cytokine that inactivates Tregs. This reduces 1515 
IL10 production by T regs, hence enhancing differentiation of Th1 cells. S19 expresses 1516 
TcpB that binds to TIRAP and MyD88, abrogating NF-κb/AP1 mediated expression of 1517 
pro inflammatory cytokines. S19ΔtcpB does not express TcpB hence, no abrogation of 1518 
NF-κb/AP1 mediated cytokine expression. Vaccination with S19ΔtcpB (Blue rectangles) 1519 
is expected to up regulate NF-κb/AP1 mediated cytokine expression, adaptive immunity 1520 
and protection against infection by wild type Brucella (green rectangles).  1521 
 1522 
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3.2 Materials and methods 1523 
3.2.1 Bacterial growth, immunization and challenge 1524 
Frozen aliquots of the vaccine preparations (Brucella abortus S19 ΔtcpB and Brucella 1525 
abortus S19) were obtained from -80°C storage and streaked on TSA plates. After three 1526 
days growth, approximately 100 colonies of the vaccine preparations were grown to log 1527 
phase. The bacterial were then adjusted to 106 CFU by use of a kletmemeter (Klett- 1528 
summersson photoelectric colorimeter, industrial model 800-3) and resuspended in 100 1529 
ul of sterile PBS. At the time of immunization, the actual CFU inoculated was 1530 
determined by serial dilution plate counts of the inoculum on TSA plates and counting 1531 
the resultant colonies.  1532 
 1533 
3.2.2  Mouse immunization and challenge 1534 
Eight-week-old male C57BL/6 female mice were purchased (Jackson Labs, Bar Harbor, 1535 
ME) and housed in approved facilities under specific pathogen-free conditions. All 1536 
experimental procedures and animal care were performed in compliance with humane 1537 
approved Texas A&M University institutional animal care regulations  (AUP 2012-156). 1538 
Mice were randomly distributed into groups of five per cage and immunized via 1539 
intraperitoneal inoculation with a single dose of vaccine containing 5x105 CFU of B. 1540 
abortus S19 or the TIR-deficient mutant strain S19ΔtcpB suspended in PBS. Control 1541 
groups were inoculated intraperitoneally with PBS alone. Following vaccination, mice 1542 
were monitored for 8 weeks prior to intraperitoneal challenge with 105 CFU wild type B 1543 
abortus 2308.  One week post-challenge, animals were placed in a chamber and 100% 1544 
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carbon dioxide introduced at a fill rate of about 10% to 30% of the chamber volume per 1545 
minute to render the mice unconscious This was followed by cervical dislocation. 1546 
Spleens were harvested, weighed and homogenized in 1 ml of PBS using an Omni prep- 1547 
sample homogenizer model 06-021 (Omni international). The sample were serially 1548 
diluted and plated in duplicate onto Farrell’s media. Three to five days post-inoculation, 1549 
bacterial counts were enumerated. Results are represented as the mean CFU per gram of 1550 
tissue ± SEM. Vaccine efficacy was evaluated by determining the log10CFU/gram of 1551 
tissue of intraperitoneal challenge bacteria recovered from spleens following tissue 1552 
homogenization and plating. The lower limit of detection was ≥5 CFU. Comparisons 1553 
between groups were made by ANOVA followed by a Student’s t test.  A p value <0.05 1554 
was considered statistically significant 1555 
 1556 
3.2.3 Determination of Brucella specific IgG2A and IgG1 levels 1557 
The levels of Brucella specific antibody in sera of mice vaccinated by S19, S19ΔtcpB 1558 
and PBS control were determined by ELISA. Approximately100µl of blood was drawn 1559 
from the tail vein of each mouse after 2, 4, 6 and 8 weeks post vaccination. The blood 1560 
was clotted at 40C after which serum was separated by centrifugation.  The serum was 1561 
then used for determination of IgG1 and IgG2a levels by ELISA. Heat killed and 1562 
sonicated B. abortus whole cell antigen was used to coat 96 well plates (Nunc-Immuno 1563 
plates) at a concentration of 0.5µg/ml. Following overnight incubation at 4°C, plates 1564 
were washed with 0.05% Tween in 1XPB (PBS-T), and blocked with 250 ul per well of 1565 
blocking buffer [0.25% (w/v) BSA]. Mouse sera was diluted at 1:100 in blocking buffer 1566 
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and added to the wells, which were then incubated for 1 hr at room temperature. The 1567 
plates were then washed 3 times with wash buffer, after which goat anti-mouse IgG1 or 1568 
IgG2a horseradish peroxidase (HRP) conjugate (eBiosciences) was added at 500ng/ml. 1569 
Incubation was then continued for one hour. The plates were then washed plates and 1570 
HRP substrate was added, and incubated with monitoring for up to 5 k times The 1571 
reaction was stopped by addition of 100 µl of 0.5M NaOH and the absorbance measured 1572 
at 450 nm (A450). One hundred µl of stop solution was added to each well and in 1573 
absorbance read at 450 nm corrected for 570 nm. IgG levels elicited by vaccination are 1574 
expressed as the mean A450±SD for each group. The significance of differences between 1575 
groups was determined by analysis of variance (ANOVA) using Prism software 1576 
(GraphPad) and difference within groups determined by Student’s t test. A p value <0.05 1577 
was considered statistically significant 1578 
 1579 
3.2.4 Measurement of serum cytokine levels 1580 
Concentrations of cytokine in mouse serum were determined using commercial ELISA 1581 
kits (eBiosciences) based on the method described by Finkelman et al., 1999 [151]. 1582 
ELISA plates (Corning star ELISA 9018) were coated with 100μl per well of capture 1583 
antibody (anti human mouse IL-5 or IFN-γ), in coating buffer (Ref# 00-0000-50 1584 
eBiosciences). The plates were then incubated overnight at 4°C. The plates were washed 1585 
three times with wash buffer. The plates were inverted on absorbent paper to drain 1586 
excess wash buffer, and the wells were then incubated in 200µl of blocking buffer at 1587 
room temperature to prevent nonspecific binding. After one hour, the wells were 1588 
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washed, followed by incubation in the presence of standards (IL-5 or IFN-γ recombinant 1589 
protein) and sera added in two fold dilutions. Serum from vaccinated mice were diluted 1590 
1:100 in assay diluent and added to triplicate wells, and the plates were sealed with Para 1591 
film.  Following overnight incubation at 4°C, the supernatants were aspirated and the 1592 
wells were washed five times with wash buffer. One-hundred µl of detection antibody 1593 
(anti mouse IL-5 or anti mouse IFN-γ) was added to each well at a concentration of 1594 
0.1- 0.25 µg/ml. and the plates were incubated for an additional hour at room 1595 
temperature. The wells were washed 5 times with wash buffer followed by the addition 1596 
of 100µl per well of Avidin HRP diluted in 1X assay diluent buffer. The plates were 1597 
sealed with parafilm and incubated for 30 minutes at room temperature. The plates were 1598 
then washed with wash buffer and 100 µl of 1XTMB (3,3',5,5'-Tetramethylbenzidine) 1599 
solution was added to each well. The plates were incubated at room temperature for 15 1600 
minutes after which 50 µl of stop solution was added to each well and absorbance at 450 1601 
nm was determined. A standard curve was plotted using recombinant protein standards 1602 
provided in the kit to determine the cytokine concentrations over time and results 1603 
expressed as the mean of concentrations ±SD for each group.  The significance 1604 
differences between groups per given time point was determined by analysis of variance 1605 
(ANOVA) using Prism software (GraphPad) followed by Student’s t test. A p value 1606 
<0.05 was considered statistically significant. 1607 
 1608 
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3.2.5 Immuno-histochemistry and histopathology 1609 
Tissues from mice were assessed to determine the degree of pathology associated with 1610 
challenge. Mice were challenged via intraperitoneal inoculation following vaccination 1611 
with either S19ΔtcpB, S19 or PBS control. One week post challenge the mice were 1612 
euthanized by CO2 asphyxiation, spleens were harvested and one random sample cut 1613 
from approximately a similar anatomical location, fixed in 10% buffered formalin, 1614 
paraffin embedded, and stained with anti CD3 antibody (Dakocytomation) 1615 
Carpentaria, CA, U.S.). Positive staining for CD3 as described with modifications after 1616 
Randal et al., [152]. Areas stained by CD3 were determined by visualization of the areas 1617 
staining brown with, the chromogen, DAB was used to label the antigenic sites. The 1618 
positive cells are visualized as have dark brown staining of the cell membrane.  The 1619 
nuclei were counterstained with hematoxylin. The slides were blinded and presented to 1620 
an independent pathologist/immuno-histochemist.  Analysis of the tissue staining for 1621 
CD3 was determined by visual examination and use of public domain image J soft ware. 1622 
A total of 4 to 5 tissues sections were examined per group. Scores were assigned on a 1623 
continuous scale of 1 to 5 (with 1 being the least T cell population and 5 being the 1624 
highest T cell populations) as described by Rizzard et al. with modifications [153].  1625 
 1626 
3.3 Statistical analysis 1627 
Calculations were done using GraphPad prism version 5.0 for Mac. Bacterial burdens in 1628 
efficacy studies were expressed as CFU ± SD and presented graphically as log10 CFU of 1629 
bacteria recovered per gram of tissue. Concentrations of cytokines in ELISA assays were 1630 
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determined using a standard curve and averages for each group (n=5) expressed as pg/ml 1631 
± SD. Comparisons were made using ANOVA followed by a Student’s t test. (p<0.05 1632 
were considered significant). For immunohistochemistry/histopathology, the stained 1633 
slides were blinded and examined by two independent pathologist quantified the CD3 1634 
staining reaction as described above.  Mean percentages of infiltrating T cells per group 1635 
were expressed as % T cell score ± SD. Comparisons between groups were made by one 1636 
way ANOVA followed by Student’s t test with p <0.05 considered significant. .  1637 
 1638 
3.4  Results 1639 
3.4.1 Immunity to B. abortus S19ΔtcpB 1640 
One of the early events in infection/vaccination with intracellular LAV bacteria is 1641 
phagocytosis by resident macrophages and the release of cytokines by these cells. The 1642 
release of proinflammatory cytokines early in vaccination is crucial in priming the 1643 
adaptive immune reaction that is essential for the clearance of infection. The bulk serum 1644 
levels of IFNγ were analyzed by ELISA. IFNγ levels were significantly elevated at two 1645 
weeks post vaccination in the serums of mice immunized with the S19ΔtcpB, in 1646 
comparison with the levels in the sera of mice vaccinated with S19 (Fig. 12). The levels 1647 
waned with time. The levels of IFNγ in the sera of the control mice were at minimal 1648 
levels throughout the vaccination period. This transient increase in pro inflammatory 1649 
cytokines in Brucella infection has been described previously [29]. 1650 
 1651 
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.  1652 
 1653 
 1654 
 Fig. 12. IFNγ levels in serum of mice vaccinated with B. abortus S19 and B. abortus 1655 
S19ΔtcpB. C57BL/6 mice were vaccinated with S19, S19ΔtcpB or PBS control. Serum 1656 
was obtained from the mice at specified time points and levels of IFNγ determined by 1657 
ELISA using a commercial kit (eBiosciences). The concentrations of cytokines were 1658 
calculated for individual mice and the means of each group ± SEM plotted against time. 1659 
The significance of differences between groups was determined by analysis of variance 1660 
(ANOVA) using Prism software (GraphPad).  A student’s t test was used to determine 1661 
the difference between means. A p value <0.05 was considered statistically significant. 1662 
 1663 
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 1664 
3.4.2 IgG2A and IgG1 ratios and levels 1665 
The IgG2A and IgG1 ODs were obtained for the mice in each group in the vaccinated 1666 
animals and plotted against time post vaccination (fig 13 b). Values obtained from 1667 
ELISAs showed elevation of IgG2A values relative to IgG1 in mice vaccinated with B. 1668 
abortus S19ΔtcpB as compared to the mice vaccinated with B. abortus S19 or PBS 1669 
(p<0.05) Tukey’s multiple comparison test). This elevation was observed towards the 1670 
latter stages of the vaccination (Fig. 13 a).  1671 
 1672 
 1673 
 1674 
 1675 
 1676 
 1677 
 1678 
 1679 
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Fig. 13 IgG2a and IgG1 levels in sera from S19 and S19ΔtcpB vaccinated mice. C57/
BL6 mice (n=5/time point) were vaccinated with 1 ×106 CFU/mouse of S19 or 
S19ΔtcpB. At 2, 4, 6, and 8 weeks post vaccination, sera were harvested from mice and 
IgG2a and IgG1 determined via ELISA. Values OD of IgG2a and IgG1 were then plotted 
for individual mice and the means of each group n=5 ± SD plotted at the selected time 
points.  1686
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 1691 
Fig 14. Spleen weights of mice vaccinated with B. abortus S19, B. abortus S19ΔtcpB or 1692 
PBS following challenge with B. abortus 2308. C57BL/6 mice vaccinated with B. 1693 
abortus S19, B. abortus S19ΔtcpB or PBS were infected intraperitonealy with 1694 
105CFU/mouse of wild- type B. abortus 2308. At one week post-infection, mice were 1695 
euthanized and the spleens were weighed to determine the degree of splenomegaly post 1696 
challenge. Results are expressed as the mean ± standard error of the mean. Differences 1697 
between weights were determined by ANOVA followed by Student’s t test  (*p<0.05). 1698 
 1699 
 1700 
3.4.3 B. abortus S19ΔtcpB mutant protects against spleen colonization following 1701 
challenge with B. abortus 2308 1702 
In order to determine whether tcpB deletion confers improved efficacy to a B. abortus 1703 
S19ΔtcpB mutant LAV as compared to B. abortus S19 vaccine, the challenged mice 1704 
were sacrificed after one week and evaluated for bacterial loads in the spleens.  The 1705 
results (Fig. 15) reveal a statistically significant 0.6 log reductions in the spleen bacterial 1706 
load in mice vaccinated with S19∆tcpB relative to those vaccinated with S19 (p<0.05). 1707 
Both vaccines provided statistically significant protection (p<0.05) with respect to naïve 1708 
mice of 2.2 logs of protection in S19 vaccinates and 2.8 logs of protection in S19∆tcpB 1709 
vaccinates (Fig.15). Reduced bacterial burdens following challenge were associated with 1710 
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reduced splenomegaly. S19ΔtcpB vaccination therefore produced a better immune 1711 
response as compared to S19 and PBS control that resulted in better protection against 1712 
splenic colonization and inflammation protection as defined by the log difference 1713 
between naïve and vaccinated (Fig. 15). 1714 
 1715 
 1716 
 1717 
 1718 
 1719 
  1720 
Fig. 15. Protection afforded to mice by B. abortus S19 and B. abortus S19ΔtcpB against 1721 
B. abortus 2308 challenge. Mice were vaccinated with 1x106 CFU B. abortus S19, B. 1722 
abortus S19ΔtcpB or PBS for 8 weeks. After the vaccination period, the mice were 1723 
challenged with 1x105CFU wild-type B. melitensis for 1 week. Mice were then 1724 
euthanized, and spleens, extracted and homogenized in peptone saline. Homogenates 1725 
were serially diluted to determine the CFU bacteria in the spleens. CFUs are expressed 1726 
as the means of the log10 of individual mice ± standard error of the mean. Differences in 1727 
colonization were determined by ANOVA and Student’s t test comparing the (*P<0.05). The 1728 
solid line represents the limit of detection which is ≥5 CFU). 1729 
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3.4.4   T cell levels in spleens of mice vaccinated by B. abortus S19ΔtcpB, S19 or PBS 1730 
following challenge with B abortus 2398  1731 
Spleens were collected from mice challenged with B. abortus 2308 following 1732 
vaccination with B. abortus vaccines S19, S19ΔtcpB or PBS (naïve control). 1733 
Immunohistochemistry for spleen samples was performed on formalin-fixed paraffin 1734 
embedded tissue sections stained with anti-CD3 polyclonal antibody. Higher levels of T 1735 
cells were observed in spleens of mice vaccinated with S19ΔtcpB and challenged with B. 1736 
abortus 2308 as measured by CD3 staining. In comparison, there were less CD3 T cells 1737 
in spleens of mice vaccinated with S19 (p (≤0.05) Students t test. Naïve mice challenged 1738 
with B. abortus 2308 had lower T cell numbers (Fig. 16). Spleen weights of mice 1739 
vaccinated with B. abortus S19, B. abortus S19ΔtcpB or PBS following challenge with 1740 
B. abortus 2308. C57BL/6 mice vaccinated with B. abortus S19, B. abortus S19ΔtcpB or 1741 
PBS were infected intraperitonealy with 105CFU/mouse of wild- type B. abortus 2308. At one 1742 
week post-infection, mice were euthanized and the spleens were weighed to determine the 1743 
degree of splenomegaly post challenge. Results are expressed as the mean ± standard error of the 1744 
mean. Differences between weights were determined by ANOVA followed by Student’s t test   1745 
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  1746 
                                                 1747 
Fig .16. T cell levels in spleens of vaccinated mice following challenge with B.abortus 1748 
2308. CD3 T cell populations in spleens were stained with anti-CD3 antibody. Slides 1749 
were scored and blinded by two independent pathologists and the averaged for each 1750 
group. Comparisons were made between groups using ANOVA and Student’s t test. 1751 
(*p<0.05).  1752 
 1753 
 1754 
3.5 Discussion 1755 
Vaccination of mice with B. abortus S19 and B. abortus S19ΔtcpB stimulated 1756 
expression of proinflammatory cytokines as were detected in serum. This has been 1757 
previously evaluated in an experiment in which serum cytokines of mice vaccinated with 1758 
S19 peaked at 2 weeks post vaccination coinciding with peak bacterial numbers [154]. 1759 
Additionally we also observed increased expression of proinflammatory cytokines  in 1760 
mice vaccinated with S19ΔtcpB at early time points  (Fig 12). The increased cytokine 1761 
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responses following S19ΔtcpB may be crucial in recruiting dendritic cells (DC) early in 1762 
vaccination. DCs then engulf the vaccine and transport it to the lymphoid organs where 1763 
it is presented to naïve T cells. T cells then differentiate into a Th1 phenotype. The Th1 1764 
phenotype is associated with increased IgG2A levels, which was confirmed in our 1765 
experiments (Fig 13). We also observed significantly larger populations of CD3 positive 1766 
T cells in spleens of vaccinated mice as compared to naïve mice. More importantly, mice 1767 
vaccinated with S19ΔtcpB had higher CD3 T cell levels than S19 vaccinates following 1768 
challenge with B. abortus 2308 (Fig 16) . Although the CD3 cells could have been a 1769 
heterogeneous population, they were associated with increased protection as evidenced 1770 
by reduced levels of challenge organisms. Reduced splenomegaly and reduced splenic 1771 
bacterial burden of B. abortus  2308 were observed in mice vaccinated with S19ΔtcpB 1772 
relative to S19 following challenge with B. abortus 2308 (Figs 14 and 15). Collectively, 1773 
these results suggest that deletion of tcpB from S19 enhanced Th1 mediated  protective  1774 
immunity against wild type challenge with B. abortus 2308. 1775 
 1776 
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CHAPTER IV 1783 
EFFECTS OF IMMUNE SPLENOCYTES ON INTRAMACROPHAGE 1784 
SURVIVAL OF BRUCELLA 1785 
 1786 
4.1  Introduction 1787 
The development of new vaccines against brucellosis has been hindered by a lack of 1788 
knowledge of the immune mechanisms responsible for protection [25]. While it is 1789 
known that cell mediated immunity and associated cytokines are responsible for 1790 
controlling infection, specific correlates of immune protection have not been defined 1791 
[76]. Invitro systems rarely reflect the overall complexity of the immune system while 1792 
analysis in animal models do not always reflect the nature of disease observed in target 1793 
species [155]. Furthermore, the use of animals and specialized housing under long-term 1794 
expensive BSL-3 conditions is not always justified. Thus, the development of an in vitro 1795 
system that models in vivo responses would facilitate the development of Brucella 1796 
vaccines and the study of anti-brucellosis control mechanisms while reducing 1797 
dependency on animal models.  For example, consider utilizing PBMC from vaccinated 1798 
ruminants to evaluate immune protection derived from enhanced intracellular killing. 1799 
The development of an invitro preclinical assay to measure Brucella vaccine efficacy 1800 
has not been reported. In order to accelerate development of Brucella vaccines, studies 1801 
were initiated studies targeting immune splenocyte mediated control of Brucella abortus 1802 
growth within macrophages and evaluating alterations in the composition and 1803 
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distributions of cellular populations in the spleens of vaccinated compared to 1804 
unvaccinated mice. 1805 
 1806 
4.1.1 Splenocyte mediated inhibition of intramacrophage bacterial growth 1807 
The primary sites of Brucella multiplication are cells of the reticuloendothelial system, 1808 
e.g. macrophages and dendritic cells [156]. Brucella establishes a replicative niche in 1809 
these cells for long term survival, a factor that is partially responsible for the chronicity 1810 
of the infection [157]. Brucella have adapted to survive and persist within the 1811 
macrophage, and their survival strategies include subversion of macrophage bactericidal 1812 
activities [158]. Virulent Brucella block various macrophage inflammatory functions 1813 
including decreased expression of pro-inflammatory cytokines and increased expression 1814 
of anti-inflammatory cytokines like IL4 and IL10 [159]. Reduction of intramacrophage 1815 
replication caused by immune lymphocytes obtained from vaccinated animals could 1816 
potentially be used as a biomarker for vaccine efficacy. We propose that an in vitro 1817 
system of co-culture of splenocytes from vaccinated mice with infected macrophages 1818 
will enhance macrophage activity and reduction of intracellular Brucella, serving as 1819 
useful biomarkers of protective immunity. Such a system could be an effective 1820 
alternative to animal challenge models and used as a predictive tool for vaccine efficacy. 1821 
Determination of protective efficacy of Brucella vaccines depends on vaccine-induced 1822 
resistance to challenge by wild type strains as determined by reduction in splenic 1823 
colonization relative to naïve mice. Additional parameters used to define immune 1824 
protection include; T cell proliferation following in vitro antigen stimulation and 1825 
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cytokine production via ELISA or ELISPOT. However, individually these parameters 1826 
have provided poor correlation with protective efficacy [160,161] . In order to 1827 
extrapolate to potential immune protection in humans, a thorough knowledge of the 1828 
correlates of protection is necessary. A feature of the immune system is the capacity of 1829 
memory T cells to mediate a faster, stronger and more effective response to secondary 1830 
pathogen challenge than naïve T cells. While CD44 antigen is a cell-surface glycoprotein 1831 
involved in cell–cell interactions, cell adhesion and migration, CD62L expression by 1832 
antigen experienced T cells corresponds to effector memory CD62Llo and central 1833 
memory CD62Lhi cells. A direct in vitro cytotoxicity assay measuring the effect of 1834 
immune lymphocytes on intra macrophage growth of bacteria is expected to mimic in 1835 
vivo vaccine activity to permit side-to-side comparison of different vaccines, and to 1836 
provide a reliable predictive measure of vaccine efficacy. We hypothesize that reduced 1837 
intramacrophage growth of B. abortus and patterns of composition and distributions of 1838 
cellular populations in the spleens will potentially serve as candidate markers for 1839 
protective immunity. To test this hypothesis we used S19ΔtcpB vaccine and S19 to 1840 
vaccinate mice and evaluated T cells (CD8+, CD4+) populations in the spleen in response 1841 
to vaccination. We further infected autologous bone marrow derived cells with B. 1842 
abortus 2308 and co cultured them with splenocytes obtained from mice vaccinated with 1843 
either S19, S19ΔtcpB or naïve mice. 1844 
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4.2 Materials and methods 1845 
4.2.1 Experimental animals and design 1846 
In this study, we vaccinated mice with two Brucella vaccines, S19 and S19ΔtcpB. The 1847 
mice were monitored for a period of 8 weeks after which splenocytes were harvested and 1848 
used in a splenocyte macrophage co-culture assay. In this assay, autologous bone 1849 
marrow derived macrophages were infected with B. abortus 2308. Immune splenocytes 1850 
were then incubated with infected macrophages and the ability to restrict Brucella 1851 
replication compared. It is hypothesized that splenocytes from mice vaccinated with 1852 
S19∆tcpB will exhibit enhanced macrophage killing activity as a result of increased 1853 
inflammatory response associated with the failure to express TcpB. Killing was defined 1854 
as the reduction in the number of colony forming units (CFUs) measured at the end of 1855 
the culture period, compared to the input CFUs. In this study, we used S19ΔtcpB vaccine 1856 
and S19 to evaluate T cells (CD8+, CD4+) populations in the spleen in response to 1857 
vaccination.  1858 
 1859 
4.2.2 Establishment of the bone marrow derived macrophages (BMDM) 1860 
Autologous bone marrow were ascetically derived macrophages (BMDM) were prepared 1861 
from C57BL/6 mice euthanized by CO2 asphyxiation followed by cervical dislocation as 1862 
described [162,163] with minor modifications. An incision, made in the midline of the 1863 
abdomen exposed the hind limb bones.  The bones were freed by clipping muscle from 1864 
the bones and by severing the bones at both ends. The femur was separated from the 1865 
tibia at the knee joint and bone marrow was flushed out with DMEM using a 5-mL 1866 
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syringe and a 25-gauge needle. A single cell suspension was formed by vigorous 1867 
pipetting, and the cells were collected using a cell strainer, washed with 5 mL of DMEM 1868 
and counted using a hemacytometer. A final count of live cells was done by use of 1869 
Trypan blue exclusion. The cell suspension was adjusted the to 2×106 live cells/mL in 1870 
complete DMEM complete supplemented with 10% (v/v) L-929-conditioned medium, 1871 
0.2 mM L-glutamine, and 0.1 mM nonessential amino acids and 100 U penicillin / 0.1 1872 
mg/ml streptomycin. The cells were cultured in 12 mL in a 10-cm culture dish with 1873 
DMEM media supplemented with L-929-conditioned medium, and the media was 1874 
replaced after every two to three days. Morphological characterization of the 1875 
macrophages was done by observation though an inverted microscope (Nikon TMS®) As 1876 
large adherent cells with large cytoplasm which is vacuolated. The nucleus tends to be 1877 
pushed to the edge of the cell and the cytoplasm may have ingested materials present.  1878 
Viability was determined at various points by trypan blue exclusion. At the end point of 1879 
culture seven days, the cells were trypsinized in 05% Trypsin-EDTA  (Invitrogen) and 1880 
transferred into 24 well plates.  The cells were seeded at 2X105 per well and cultured for 1881 
24 hours before infection with Brucella. 1882 
 1883 
4.2.3 Macrophage infection and splenocyte co-cultivation 1884 
Confluent adherent macrophage monolayers (BMDM) in 24 well tissue culture plates 1885 
were infected at a multiplicity (MOI) of 1:100 (bacterium-to-BMDM) with B abortus 1886 
2308 suspended in DMEM and incubated for 30 minutes. Following uptake, the media 1887 
was removed, the monolayer was rinsed with antibiotic-free DMEM, and media 1888 
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supplemented with 50µg/ml gentamicin was added to kill extracellular bacteria and 1889 
incubation continued for an additional 30 minutes.   At this point the cell monolayers 1890 
were rinsed as above and replaced with antibiotic-free DMEM supplemented with 1891 
30µg/ml gentamicin. Single cell suspensions of splenocytes derived from vaccinated 1892 
mice were added to the monolayers 30 minutes later at 1x107 cells per well. Cellular 1893 
viability was determined by trypan blue exclusion staining and values above 95% were 1894 
considered to be acceptable.  On days 0, 1, 2 and 3 the monolayers was washed three 1895 
times with PBS and lysed with 0.5% (v/v) aqueous Tween-20 and plated on TSA plates 1896 
to enumerate the number of intracellular bacteria. Cell viability was measured using 1897 
cytotox 96 LDH release assay (Promega). To generate immune splenocytes, we 1898 
vaccinated mice with two Brucella vaccines, S19 and S19ΔtcpB. The mice were 1899 
monitored for a period of 8 weeks after which splenocytes were harvested using standard 1900 
techniques as described by De Pascalis [164] and used in a splenocyte macrophage co- 1901 
culture assay.  1902 
 1903 
4.2.4 Preparation of lymphocytes and flow cytometry 1904 
Single-cell suspensions of spleens were generated for in vitro culture and flow cytometry 1905 
by standard techniques, as previously described [164]. No bacterial CFU were detected 1906 
in organ homogenates at the time of harvest. The absence of vaccine strain (LAV) in 1907 
organ homogenates at the time of harvest was verified by serial plating and bacterial 1908 
culture of TSA. Cell viability was assessed by exclusion of trypan blue. Multiparameter 1909 
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analyses were performed using a panel of murine cell surface markers with a Becton, 1910 
Dickinson LSR II flow cytometer (San Jose, CA) and analyzed using FlowJo software 1911 
(TreeStar, Inc) [164]. 1912 
 1913 
4.2.5 Flow cytometry for identification of splenic T memory cells 1914 
 Mice were vaccinated intraperitonealy with B. abortus S19ΔtcpB, B. abortus S19 or 1915 
PBS control and euthanized eight weeks post vaccination by CO2 asphyxiation followed 1916 
by cervical dislocation according to AUP number 2012-156. Single cell suspensions of 1917 
splenocytes prepared as described above were aseptically harvested and immediately 1918 
stained with a combination of anti-CD8 (PerCP-cy5.5 BD-Biosciences) anti CD62L 1919 
(FITC clone MEL-14, BD Bioscience, CA, USA), anti CD44 (APC clone IM-7, BD 1920 
Bioscience, CA, USA), and pacific blue conjugated rat anti-mouse CD4a (clone RM4-5, 1921 
BD Bioscience, CA, USA) to determine the fraction of memory T cells 1922 
(CD4+CD44+CD62L+) among the CD4+ T cell population of vaccinated mice. Stained 1923 
splenocytes were analyzed on a BD Aria II FACS (CA, USA) acquiring 10,000 events, 1924 
and the output was analyzed using FlowJo (Tree Star, Ashland, OR) and Prism 1925 
(GraphPad software, LA Jolla, CA). 1926 
 1927 
4.2.6 Evaluation of cytokine levels in splenocyte-macrophage co cultures 1928 
Supernatants recovered from in vitro co-cultures were assayed using standard sandwich 1929 
ELISA, according to the manufacturer’s instructions (BD Pharmingen, San Diego, CA). 1930 
Quantification of IFNγ and IL-5, were assessed by comparison using recombinant 1931 
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protein standards (BD Pharmingen). Standards provided in the kit were used in the 1932 
ELISA alongside the test supernatants. ODs obtained from standards were used to plot a 1933 
standard curve of OD against concentrations. A trend line was derived from the curve, 1934 
providing a function that was used to calculate the concentrations. The concentrations 1935 
were expressed as mean pg/ml ±SD. Differences between means were determined by 1936 
ANOVA followed by a student’s t test and values of p≤0.05 were considered significant. 1937 
 1938 
4.2.7  Measurement of cell viability (the LDH assay) 1939 
LDH release from the co-culture assays was measured by the cytotox 96®Non- 1940 
cytotoxicity assay according to the manufacture’s instructions (Promega). Supernatants 1941 
were collected from wells with splenocyte-macrophage co-cultures, at 24, 48 and 72 1942 
hours post infection. Control wells left uninfected (Spontaneous Release) or incubated 1943 
with lytic reagent (Maximum Release). Supernatants were incubated with 50µl of the 1944 
CytoTox 96® incubate at room temperature, protected from light, for 30 minutes. 50µl 1945 
of the Stop Solution was added and absorbance read at 490nm. The percentage of 1946 
cytotoxicity was calculated as (Infection-induced Release – Spontaneous Release/ 1947 
Maximum –Spontaneous Release), and presented as the average (n=5) of % cytotoxicity 1948 
± SD. 1949 
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4.3 Results 1950 
4.3.1 Evaluation of T cell percentages in isolated splenocytes 1951 
Ex vivo isolated splenocytes stained for the percentage of CD8+ and CD4 T+ cells and 1952 
analyzed revealed elevated bulk CD8+T cells in splenocytes of mice vaccinated 1953 
intraperitonealy with either B. abortus S19 or B. abortus S19∆vjbR relative to the 1954 
control mice. However there was no significant difference in the population of CD8+T 1955 
in mice receiving either vaccine strain (Fig. 17 a). No significant difference was detected 1956 
in the overall CD4+ T cell population in splenocytes derived from either vaccinated or 1957 
control mice. However, analysis of the memory CD4+ T cells revealed an increase 1958 
within the CD4+ T cell fraction (Fig. 17 b). In addition, the memory CD4 T cell fraction 1959 
was significantly elevated in splenocytes obtained from mice vaccinated with the 1960 
S19∆tcpB mutant relative to the mice vaccinated with S19 (Fig 18 a and b).  1961 
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Fig. 17 a) Gating of total CD4+ and CD8+ T cells in splenocytes obtained from 1963 
vaccinated mice. Mice were immunized with B. abortus S19 or B. abortus S19∆vjbR at 1964 
1X105 CFU per mouse. After 8 weeks, splenocytes were harvested and stained with 1965 
flourochrome-conjugated antibodies specific for CD4+ and CD8+ T cells. a) Gating 1966 
strategy for phenotypic analysis of CD4 and CD8 T cells from splenocytes of vaccinated 1967 
mice. Cells were gated using Aria flow cytometer and their percentages expressed as a 1968 
total percentage of T Cells. 1969 
 1970 
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Fig. 17 b) Percentages of CD4+ and CD8+ T cells in splenocytes obtained from 1975 
vaccinated mice. Graphical representation of total CD4+ and CD8+ T cells from spleens 1976 
of vaccinated mice (n=5). Data were expressed as means ± SD of samples and 1977 
comparisons made between treatment groups using ANOVA and analyzed using 1978 
Student’s t test (*p-values <0.05)  1979 
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4.3.2  Analysis of the memory T cell population within CD4+ T cell fraction of 
splenocytes from vaccinated mice 
Splenocytes harvested from mice vaccinated intraperitonealy with B. abortus S19, B. 
abortus S19ΔtcpB or PBS were evaluated for presence of memory T cells. The markers 
used did not allow differentiation between hi and lo memory cells. Elevated percentage 
increases in memory cells bearing CD44+ CD62L+markers were found in splenocytes of 
mice vaccinated with B. abortus S19ΔtcpB mutants (ANOVA and Student’s t test 
p<0.05) in comparison to those vaccinated with B. abortus S19.  1991
86 
1992
Fig. 18 a) Gating strategy for phenotypic analysis of CD44+ and CD62L+ cells in the 1993
CD4 fraction of splenocytes from vaccinated mice. Cells were gated using Aria flow 1994
cytometer and their percentages expressed as a total percentage of T Cells. 1995
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Fig. 18 b) Analysis of the memory CD4+CD44+CD66L+ T cell population within  2003
CD4+ T cell fraction of splenocytes from vaccinated mice.  Individual mice were  2004
Immunized with B. abortus S19 or B. abortus S19∆vjbR with 105 CFU. Splenocytes  2005
were harvested 8 weeks post-vaccination and stained with flourochrome-conjugated  2006
antibodies against CD4+, CD44+ and CD66L+. CD4+CD44+CD66L+ cells were gated  2007
using Aria flow cytometer and expressed as a percentage of CD4+ T cells. 2008
Data are expressed as means ± SEM of n=5 and comparisons made between treatment 2009
groups using ANOVA and the Student’s t test (p-values <0.05) 2010
2011
2012
2013
2014
4.3.3 Splenocyte mediated killing of intracellular Brucella
Splenocytes isolated from mice vaccinated intraperitonealy with B. abortus S19, B. 
abortus S19ΔtcpB or PBS were co-cultured with BMDM infected in vitro with B. 2015
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abortus 2308. In addition, the intracellular bacterial burdens of BMDM cultured without 2016 
addition of splenocytes (Blanks) were monitored.  B. abortus 2308 replicated efficiently 2017 
in BMDM, and the addition of immune splenocytes accelerated intramacrophage 2018 
inhibition of replication of wild type Brucella (Fig. 19). Enhanced killing of B. abortus 2019 
2308 occurred in co-cultures using splenocytes derived from mice vaccinated with B 2020 
abortus S19ΔtcpB relative to splenocytes obtained from B. abortus S19 vaccinated mice 2021 
(P ±0.05). Naïve splenocytes did reduce the killing of intra-macrophage bacteria.  2022 
 2023 
 2024 
 2025 
 2026 
 2027 
 2028 
 2029 
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a) 2031 
 2032 
Fig. 19:  Effect of splenocytes from vaccinated and non-vaccinated mice on 2033 
intramacrophage survival of B. abortus 2308. BMDM were generated from C56BL/6 2034 
mice and plated at 2X105 in 24 well plates. The BMDMs were infected with wild type B. 2035 
abortus 2308 for one hour at an MOI of 100. Splenocytes obtained from age matched 2036 
C57BL/6 mice were added at 1, 2 and 3 days, (spleenocyte cells were obtained from 2037 
mice vaccinated with a) PBS, b) S19 c) S19ΔtcpB) the cells were lysed with 0.5% tween 2038 
20 in sterile water. The lysed cells were serially diluted and plated on TSA plates. The 2039 
plates were incubated at 37°C and numbers of colonies enumerated. The bacterial 2040 
burdens were expresses as log 10CFU/ml and plotted against time. Values are the means of 2041 
individual mice were expressed as CFU ± SD. The doted line represents the limit of detection 2042 
 which is ≥5 CFU.  2043 
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Fig. 19 (Continued) 2051 
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4.3.4 IFNγ expression by sensitized splenocytes 2060 
To identify a potential correlate of immune protection, the BMDM monolayer 2061 
supernatants were evaluated for IFNγ content. Supernatants from the co-culture assay 2062 
were harvested at various times, and the IFNγ level was evaluated using ELISA. Higher 2063 
levels of IFNγ were detected in cultures that received splenocytes from mice vaccinated 2064 
with B. abortus S19ΔtcpB as compared with those vaccinated with S19 (P ≤ 0.05)	 2065 
Although attempted, no Th2 cytokine IL5 was detected by T cells in the co-culture 2066 
assays. 2067 
 2068 
 2069 
 2070 
 2071 
 2072 
 2073 
 2074 
 2075 
 2076 
 2077 
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 2078 
Fig. 20. Concentrations of IFNγ from in vitro cultures of immune splenocytes and 2079 
infected macrophages.  BMDM from C56BL/6 mice were plated at 2X105 in 24 well 2080 
plates and infected with wild type B. abortus 2308 for one hour at an MOI of 100. 2081 
Splenocytes obtained from age matched C57BL/6 mice vaccinated with B. abortus S19,  2082 
B. abortus S19ΔtcpB, PBS or media without splenocytes were added. At 1, 2 and 3 days, 2083 
supernatants were collected and analyzed for levels of IFNγ. Data were expressed as 2084 
means ± SD for each group (n=5) and comparisons made between treatment groups 2085 
using two way ANOVA analyzed using Tukey’s Multiple Comparison test (p-values 2086 
<0.05=*) were considered significant. 2087 
 2088 
 2089 
4.3.5  Measurement of LDH Release  2090 
LDH release from cells is a measure of cytolysis as a result of necrosis, apoptosis or 2091 
pyroptosis. The LDH assay was used to determine the percentage viability of the cells in 2092 
the spleenocyte macrophage co-culture assay. Although cell lysis in the assays was 2093 
minimal (less than 15%), more cell lysis was observed in co cultures incubated with 2094 
splenocytes obtained from S19 and S19 vaccinated mice than the macrophages with no 2095 
splenocytes. (ANOVA and Tukeys Multiple comparison Test  p≤ 0.05).  This difference 2096 
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may be attributable to multiple factors including, the cytotoxic activity of the sensitized 2097 
splenocytes for infected cells or natural attrition. 2098 
 2099 
 2100 
  2101 
 2102 
Fig. 21. LDH release from splenocyte-macrophage culture assays. 2103 
Supernatants were collected from co-cultures of splenocytes from mice vaccinated with 2104 
B. abortus S19, B. abortus S19ΔtcpB, or PBS and macrophages only co-cultures. 2105 
Cytotox96 non-radioactive assay was used to determine the levels of LDH released by 2106 
the cells. ODs were measured at 530nm and % cytotoxicity calculated as LDH release 2107 
release/Maximum LDH release.  Percent LDH release is expressed as mean of three 2108 
results ± SD. Comparisons between means were analyzed by ANOVA followed by 2109 
Tukeys multiple comparizon test (* P≤ 0.05) 2110 
 2111 
 2112 
4.4 Discussion 2113 
Previously published results indicate that mice vaccinated with Brucella LAV mount an 2114 
immune response that results in differentiation of splenic T cells [36]. Upon a second 2115 
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encounter with the pathogen, T cells proliferate and express pro-inflammatory cytokines 2116 
and effector mechanisms that enhance the intramacrophage killing or inhibition of 2117 
replication of the pathogen [165]. CD4+CD44+CD62L+ are memory CD4 T cell obtained 2118 
in the spleen and respond robustly following secondary encounter with the pathogen. 2119 
Memory CD4+ T and CD8+T cells have been classified into effector (CD44CD62LLo) 2120 
and central (CD44+CD62L+ hi) [166]. Central memory cells express CD44 homing 2121 
receptors that locate them in the spleen and lymph nodes, from where they undergo 2122 
robust proliferation on second encounter with the antigen, this gives long term protective 2123 
memory to the host[166].  2124 
Our data confirmed that vaccination with the B. abortus S19ΔtcpB LAV mutant induced 2125 
the highest frequency of CD4+ T cells in the spleen (Fig. 18), which in turn may provide 2126 
the benefit of long-term protection against B. abortus 2308 challenge.  Flow cytometry 2127 
of mice vaccinated with PBS did not have a significant increase in memory T cells; 2128 
hence, the high numbers of T cells was attributed to response following vaccination. 2129 
This may suggest that tcpB deletion results in up regulated transition of CD4 T cells to 2130 
memory cells and is consistent with overall immune protection.    2131 
 Splenocytes obtained from mice vaccinated with Brucella LAV vaccines accelerated the 2132 
killing activity, which may be attributed to the increased IFN-γ detected, although 2133 
alternative explanations are possible and require further investigation (Figs 19 and 20).  2134 
Splenocytes obtained from vaccinated mice are expected to contain high levels of 2135 
sensitized T cells in addition to other cells like NK cells, gamma delta cells.  These may 2136 
participate in specific and on specific killing of intramacrophage bacteria. 2137 
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From our experiments, we determined the overall cell lysis in the assays, more cell lysis 2138 
observed in cultures of splenocytes obtained from S19 and S29 tcpB vaccinated mice, 2139 
this was however minimal (Fig 21) and may be attributed to among other factors, the 2140 
presence of sensitized T cells. Although the less lysis was observed in cultures with 2141 
splenocytes obtained from PBS vaccinated mice, it was not significant. In general, this is 2142 
explained by the principle that splenocytes isolated from vaccinated mice are rich in 2143 
pathogen specific T cells following a prior encounter with the pathogen, however other 2144 
factors may also be responsible for the killing, including, NK cells, γδ cells [167]. 2145 
Infected macrophages process and present Brucella pathogen to these sensitized 2146 
splenocytes in the context of MHC class II. The splenocytes are activated and secrete 2147 
IFNγ, which in turn activates the macrophages to kill the intracellular bacteria [168]. 2148 
This assay could be further developed and used to quantitate the efficacy of the vaccine. 2149 
Factors that may be considered to improve the assay include correcting for death of 2150 
effector and/or targets by attrition. Our studies also provide evidence that splenocytes 2151 
obtained from mice vaccinated with S19ΔtcpB are associated with enhanced 2152 
intramacrophage killing of Brucella infected macrophages.   These studies provide 2153 
evidence that vaccines of unknown efficacy may be evaluated by infecting macrophages 2154 
with wild type Brucella and used as co-cultured targets with immune splenocytes from 2155 
LAV vaccinated animals. 2156 
 2157 
 2158 
 2159 
 2160 
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CHAPTER V 2161 
CONCLUSIONS AND SUMMARY 2162 
 2163 
Live attenuated vaccines against Brucella provide elevated protection against wildtype 2164 
challenge, but exhibit varying levels of safety [25].  As a result, there remains a 2165 
significant level of concern related to their use both in animals and humans, and as a 2166 
result concerted efforts are needed to improve their safety and effcicacy [26].  These 2167 
efforts include the construction of stable deletion mutants lacking virulence and the 2168 
potential to revert to virulent forms [26] . Although these goals are now achievable, they 2169 
can restrict immune potential if not carefully formulated. An alternative line of 2170 
investigation to supplement the approach is to define the host immune response with the 2171 
intent of identifying protecive mechanisms and to target pathway components in an 2172 
effort to enhance protection. As a stealth pathogen, Brucella enters the cell with minimal 2173 
activation of the host innate immune response [57]. 2174 
In this study, we compared the ability of two LAV Brucella vaccines, B. abortus S19 2175 
and the B. abortus S19ΔtcpB deletion to stimulate host immune reaction. We evaluated 2176 
their capacity to stimulate host innate and adaptive immune responses in addition to 2177 
promoting T cell memory differentiation and protective efficacy. It was expected that the 2178 
mutant would induce a stronger host innate as well as adaptive immune respnses and 2179 
provide an enhanced immune protection. Following vaccination, there was a significant 2180 
elevation of inflammatory IFNγ in the serum of mice vaccinated by the B. abortus 2181 
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S19ΔtcpB mutant as compared to the parent B. abortus S19 (Fig. 12). The increased 2182 
serum IFNγ, however, waned with time.  This could be explained by the reduced tissue 2183 
bacterial loads. The initial increased inflamation, could be attributed to the enhanced 2184 
inflammatory properties of the mutant. This initial inflamation could play a critical role 2185 
in providing the adjuvant effect that boosts the hosts immune reaction to the LAV 2186 
vaccine and recruiting antigen presenting cells to the site of the vaccine. A significantly 2187 
elevated IgG2a isotype was observed late post vaccination in mice vaccinated with B. 2188 
abortus S19∆tcpB in comparison with mice vaccinated with B. abortus S19 and the non- 2189 
vaccinated controls (Fig. 13). Since Th1 immunity is associated with elevated IgG2a 2190 
titers, it was concluded that the mutant skewed the immune response toward early T cell 2191 
differentiation, which is critical in development of the important memory T cells.  2192 
Indeed, we also evaluated the levels of IFNγ in serums of Brucella LAV vaccinated mice 2193 
by ELISA. We observed that there were elevated levels of IFNγ in serum of mice 2194 
vaccinated by Brucella LAV. These levels were further elevated in mice vaccinated with 2195 
B. abortus S19ΔtcpB vaccine. Since Brucella is an intracellular pathogen, it replicates 2196 
inside the macrophages, activating the MyD88 signaling pathways. This activation may 2197 
be downstream of TLR9, TLR2 or TLR4. However, greater effects have been observed 2198 
in MyD88 mediated pathways, as evidenced in reduced bacterial clearance in myD88 2199 
knock out mice. TLR activation enhances the expression of IL12, IL6 and other IFNγ 2200 
cytokines. These cytokines act on T cells causing differentiation into the Th1 phenotype. 2201 
Th1 T cells produce IFNγ which acts on macrophages to enhance intracellular killing of 2202 
the intracellular Brucella [144]. This provides a plausible explanation for the elevated 2203 
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IFNγ levels in Brucella LAV vaccinated mice.  Brucella, however, expresses TcpB, a 2204 
protein that subverts TLR signaling and reduces expression of proinflammatory 2205 
cytokines [33]. Deletion of tcpB from the S19 vaccine strain reduced the immune 2206 
subversive effects and resulted in up regulation of IFNγ. Splenocytes from mice 2207 
inoculated with the B. abortus S19∆tcpB deletion mutant had increased CD4+ T memory 2208 
cells. Since TcpB has been implicated in the disruption of mTOR signaling pathway, its 2209 
absence may be expected to enhance memory cell differentiation [36], and the observed 2210 
increase in the number of CD4+ memory T cells is consistent with this prediction. 2211 
Splenocytes obtained from LAV vaccinated mice also exhibited higher killing activity in 2212 
a co-culture with B abortus 2308 infected bone marrow derived macrophages. 2213 
Splenocytes obtained from mice immunised with S19ΔtcpB had enhanced killing 2214 
activity towards BMDMs infected with B. abortus 2308. This difference could be 2215 
attributed to elevated levels and/or improved performance of memory T cells among the 2216 
splenocytes derived from B. abortus S19ΔtcpB vaccinated mice. Reduced spleen 2217 
weights occurred in B. abortus S19ΔtcpB vaccinated mice challenged with B. abortus 2218 
2308. This suggests that vaccine B. abortus S19ΔtcpB afforded a better protection 2219 
against B. abortus 2308 than B. abortus S19. This suggests that ΔtcpB deletion confers 2220 
improved immunogenicity to B. abortus and better protective efficacy against virulent B. 2221 
abortus 2308. 2222 
The high CD4+T cell memory cell population in the spleens observed in this study is 2223 
consistent with high T cell levels in mice vaccinated with B. abortus S19 tcpB and 2224 
challenged with B. abortus 2308. Importantly, the significantly higher levels of CD4+T 2225 
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memory cells observed in mice vaccinated with B. abortus S19ΔtcpB corresponded with 2226 
the degree of splenomegaly in these mice relative to those vaccinated with B. abortus 2227 
S19 or in the naïve controls. This effect is attributed to CD4+T memory cells as it has 2228 
been previously reported that IFNΥ secretion is related to CD4+T cells levels [169]. This 2229 
evidence strongly suggests that the presence of TcpB  restricts vaccine efficacy and 2230 
deletion of TcpB should be pursued to improve vaccine efficacy. Reduced spleen 2231 
bacterial burden following B. abortus 2308 challenge in B. abortus S19ΔtcpB vaccinated 2232 
mice is consistent with improved protective efficacy of the LAV candidate.  2233 
A second TIR protein encoded by the locus (BruAbi0725), designated Btp2 has recently 2234 
been identified in Brucella, and has been found to bind to and abbrogate NF-κB 2235 
mediated cytokine production [32]. The mechanism of action has been defined as 2236 
inhibition of binding to MyD88 and subverting TLR signaling function [32]. Btp-2 2237 
deletion mutants in wild type B. abortus exhibited increased expresion of 2238 
proinflammatory cytokiens in immunocompromised mice [32,86]. This extends the 2239 
impact of TIR protein modulation of inflammatory response, a key factor in vaccine 2240 
efficacy. However, deletion of TIR in wild type strains does not significantly alter the 2241 
virulence of bacteria [58]. tcpB deletion enhances the immunogenic properties of  LAV 2242 
while preserving most of the pathogen invasive properties. This, phenomena can be 2243 
exploited in live attenuated vaccines to improve efficacy while maintaining safety. 2244 
Further studies need to be performed to determine the effect of Btp2 gene deletion in live 2245 
attenuated bacterial vaccines. 2246 
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While it is known that cell mediated immunity and associated cytokines are responsible 2247 
for controlling Brucella infection, the correlates of protection have not been adequately 2248 
defined. In addition it is difficult to study numerous interactions of the components of 2249 
the immune system in vivo. Current studies to identify new vaccine candidates involve 2250 
use of animals housed in expensive BSL-3 conditions that are challenged with virulent 2251 
organisms after vaccination. The development of an in vitro system that models in vivo 2252 
responses would facilitate the development of Brucella vaccines and the study of 2253 
brucellosis control mechanisms besides reducing the number of animals and cost of 2254 
vaccine trials. The development of in vitro preclinical assays that mimic in vivo efficacy 2255 
of Brucella vaccines not been developed. In order to accelerate development of Brucella 2256 
vaccines, we have initiated development of an in vitro functional assay as a correlate of 2257 
protective activity of Brucella vaccines. In this assay, Brucella protection was evaluated 2258 
by targeting the reduction of Brucella abortus 2308 growth within macrophages. 2259 
Splenocytes obtained from mice vaccinated with vaccines B. abortus S19 or  B. abortus 2260 
S19ΔtcpB or naïve mice were used as effectors and co-cultured with B. abortus 2308 2261 
infected macrophages. We observed that following one to three days of incubation; the 2262 
intramacrophage replication of Brucella was dramatically reduced. Importantly, 2263 
splenocytes obtained from mice vaccinated with B. abortus S19ΔtcpB exhibited 2264 
enhanced killing activity against B. abortus 2308 infected macrophages as compared to 2265 
those obtained from animals vaccinated with B. abortus S19. This result suggests that 2266 
the splenocyte killing activity may be associated with in vivo protective ability. 2267 
Supernatants obtained from the assays were also evaluated for levels of pro- 2268 
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inflammatory cytokine Th1 cytokine IFNγ and anti-inflammatory Th2 cytokine IL5. 2269 
Supernatants obtained from the co-cultures that exhibited reduced bacterial burdens had 2270 
higher levels of IFNγ cytokines and virtually undetectable levels of IL5 cytokines. This 2271 
is in agreement with the role of IFNγ in promoting intramacrophage killing of Brucella 2272 
and the subsequent low levels of IL-5. Inhibition of intramacrophage burdens of Brucella 2273 
was significantly reduced on day one following pre incubation with splenocytes despite 2274 
minimal levels of  IFN- γ in the supernatants, pointing towards an alternative killing 2275 
mechanism deployed in the assay. A possibility of other mechanisms includes 2276 
expression of other pro inflammatory cytokines and chemokines.  2277 
 2278 
5.1 Future directions 2279 
TcpB occupies a central control point in modulating the LAV Brucella induced host 2280 
immune responses. There is need to quantitate the relative contribution of each action of 2281 
TcpB to immune subversion. This will aid in explaining the pathogenesis of Brucella 2282 
and assist in more logically designed vaccines and chemotherapeutic agents. 2283 
Additionally, other Brucella effectors like T4SS VceC seem to act in contravention to 2284 
TcpB by activating the UPR and enhancing cytokine expression [97]. It may be possible 2285 
that the timing and balance of expression between these effectors is different so that each 2286 
activity is designed to achieve a specific goal at a certain point in the cycle of the 2287 
pathogen.  The overall mechanism by which TcpB causes ER restructuring and 2288 
subsequent activation of UPR has not been experimentally determined. Paclitaxel, a 2289 
cancer drug also causes microtubule restructuring at low concentrations, like TcpB 2290 
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[170]. A comparison of the two on the effects of the cell cycle could shed light on the 2291 
mechanism of TcpB action. In conclusion, tcpB deletion provides a good secondary 2292 
deletion that can be made in the current available Brucella LAV as a means of 2293 
improving efficacy. This will remove the immune subversive action that may 2294 
compromise the vaccine as well as provide the much needed adjuvant effect to enhance 2295 
efficacy and longevity of protection. In addition, the inherent safety of the vaccine will 2296 
not be compromised. The results of the co culture assay may demonstrate a practical and 2297 
reproducible way of assessing Brucella vaccines. Vaccinated animals can serve as a 2298 
source of effector cells that can be used to probe activity against wide range of targets 2299 
(macrophages infected with a variety of bacteria). Vaccine specific effector cells can 2300 
then be clonally expanded and stored. The spectrum of effector cells can then be used in 2301 
future to probe multiple targets as a test for vaccine efficacy. Clonally expanded T cells 2302 
can be used to identify specific epitope targets obtained from pathogen peptides in an 2303 
effort define the responding MHC class I or class II epitopes. These epitopes could then 2304 
be designed as potential peptide vaccines. Further development of this assay will be 2305 
necessary for testing multiple vaccines to enhance application of the system to Brucella 2306 
LAV. Such an assay could then be used to predict vaccine efficacy while reducing the 2307 
time and cost of vaccine testing. 2308 
 2309 
 2310 
 2311 
 2312 
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